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The secretory pathway in cells is critical for the precise synthesis, modification 
and directed transport of proteins, lipids, and carbohydrates.  Phospholipid 
metabolizing enzymes are thought to contribute to the transport of cargo within 
the cell by altering the lipid composition of membranes and allowing them to 
form transport carriers including vesicles and membrane tubules.  The specific 
phospholipid-modifying enzymes have not been fully discovered, but evidence 
suggests roles for both lysophospholipid acyltransferases (LPATs) and 
phospholipase A2 (PLA2) enzymes in mediating membrane trafficking.   
 
Using inhibitor-based studies, PLA2 activity has been shown to be important 
for Golgi trafficking and structure.  PLA2 antagonists block the formation of 
membrane tubules from the Golgi.    Conversely, LPAT inhibitors cause the 
formation of Golgi membrane tubules.  From those observations, we 
hypothesize a role for PLA2 enzymes in generating membrane tubules and a 
role for LPATs in the negative regulation of membrane tubules, which are 
important for Golgi structure and function.    
 
In this study I explore the functions of a novel protein, lysophosphatidic acid 
acyltransferase 3 (LPAAT3), in phospholipid metabolism, maintaining Golgi 
structure, membrane trafficking, and membrane tubule regulation.  Using 
 biochemical approaches, I have shown that LPAAT3 generates phosphatidic 
acid in Golgi membranes.  LPAAT3’s activity is critical for maintaining a 
compact Golgi structure.  Furthermore, LPAAT3 expression alters both 
retrograde and anterograde trafficking by regulating the formation of 
membranes tubules from the Golgi.   
 
The role of PLA2 enzymes in trafficking was also explored using inhibitors to 
study trafficking from the Trans Golgi Network (TGN) to the cell surface.  PLA2 
inhibitors blocked trafficking to the plasma membrane and caused the 
accumulation of cargo in the TGN.  Furthermore, the formation of TGN 
tubules, whose fission is regulated by protein kinase D (PKD), is dependent on 
PLA2 activity as well.   
 
I show that both LPATs and PLA2s are important factors in regulating 
membrane trafficking within cells.  They do this by altering the phospholipids 
within membranes and by promoting or regulating the formation of membrane 
vesicles and membrane tubules.  These results contribute to our 
understanding of membrane trafficking and the phospholipids involved in those 
pathways. 
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CHAPTER 1 
General Introduction 
 
All living cells require a process by which newly synthesized proteins 
are directed to locations within or outside of the cell so they can perform their 
enzymatic or structural functions.  In eukaryotes, many proteins, lipids, and 
carbohydrates are transported through a series of membrane-bound 
organelles that function in the synthesis, modification, and directed transport of 
these molecules.  This is called the secretory pathway, and is important for 
key cellular functions including the release of insulin into the blood stream 
from pancreatic β cells, the production and release of brain chemicals into the 
synapses of neurons, and the release of immunoglobulins from lymphocytes to 
name a few.     
The secretory pathway begins at the endoplasmic reticulum (ER), 
where proteins are synthesized and modified.  From the ER, proteins are 
transported to another organelle called the Golgi complex.  Unlike the ER, the 
Golgi is a series of membrane-encased compartments that continue with the 
modifications required for a protein to function properly.  From the Golgi, 
protein, lipid, and carbohydrate cargo is then sorted and transported to the 
plasma membrane of the cell or another organelle in the endosome network.  
In addition to the secretory pathway, a reverse directional transport of cargo 
also occurs that can recycle materials from the plasma membrane back to the 
Golgi, consume nutrients and other factors from the extra-cellular 
environment, or regulate cell surface components.  The Golgi complex is 
formed and maintained by the convergence point of many intracellular 
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transport pathways; it directs cargo from the ER, the plasma membrane, and 
endosomes making the Golgi an important transport center.   
Although technologies including the electron microscope, fluorescent 
protein chimeras, and powerful genetic screens have provided great insights 
into how the secretory and membrane trafficking pathways work, there still 
remain many unknown aspects of these processes including how transport 
carriers are formed and how the Golgi is organized.   
 
The Endoplasmic Reticulum 
The ER is a web-like network of interconnected membrane tubules and 
membrane sheets that generate a large, convoluted lumen separated from the 
cytosol.  The ER is where many lipids are synthesized (smooth ER) and where 
many proteins are synthesized (rough ER).  Some mRNA molecules encode 
an ER signal sequence that when synthesized results in a signal recognition 
particle (SRP)-dependent translational pause followed by translocation of the 
mRNA, ribosome, and SRP-bound nascent peptide to the ER membrane 
where translation is completed (Blobel and Dobberstein 1975; Blobel and 
Dobberstein 1975; Blobel 1987).  The resulting protein is either inserted into 
the lumen of the ER or into the membrane itself.  Proteins are then post-
translationally modified by glycosylation and di-sulfide bond formation and, 
with the help of chaperones, correctly folded into their tertiary structure.   
 
The Golgi Complex 
The Golgi complex is just that, complex, and has been surrounded by 
controversy since its discovery.  Camillo Golgi was the first to describe the 
Golgi as a basket-like structure adjacent to the nucleus in neurons (Golgi 
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1989).  The existence of the Golgi was disputed until the advent of the electron 
microscope, which allowed the visualization of cellular structures that could not 
be seen with a light microscope (Dalton and Felix 1954; Dalton and Felix 
1956).  The function of the Golgi, however, was unclear until George Palade 
proposed a model for the secretory pathway that included the Golgi complex 
(Palade 1975).  This model was the foundation for our understanding of the 
Golgi.   
The Golgi is a series of stacked membrane-bound compartments called 
cisternae that each has unique properties.  The cisternae are ordered as cis-
Golgi, medial-Golgi, trans-Golgi, and TGN.  An intermediary compartment 
called the ER-Golgi-Intermediate Compartment (ERGIC) is a liaison between 
the ER and the Golgi.  Each of the cisternae is functionally and biochemically 
distinct.  From cis to trans the pH of the lumen decreases and the cholesterol 
levels in the membrane increase (Anderson, Falck et al. 1984; Bretscher and 
Munro 1993).  The protein content of each cisterna is also specialized for each 
compartment.  Resident enzymes in the cis compartment covalently link 
simple sugar molecules onto proteins.  In the medial and trans compartments, 
additional complex sugars are added on to this foundation. The Golgi 
cisternae comprise a series of compartmentalized sequential reactions (Hart 
1992).   
In most mammalian cells, the Golgi is located adjacent to the nucleus at 
the microtubule organizing center (MTOC) where the minus ends of 
microtubules converge.  The cytoskeleton is intimately linked to the structure 
and the function of the Golgi as a nexus for membrane transport.  Inhibitors 
that disrupt the microtubule cytoskeleton network also cause the Golgi to 
fragment and become decentralized (Thyberg and Moskalewski 1985).  
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Similarly, when a cell undergoes mitosis and the microtubule network 
dissociates and scatters, the Golgi scatters too (Kreis 1990).  After cell 
division, the Golgi complex reforms at the MTOC by transport along the 
reformed cytoskeleton with the aid of dynein, a motor protein that moves from 
the plus end to the minus end of microtubules (Burkhardt, Echeverri et al. 
1997).  As expected, disruption of dynein also leads to Golgi fragmentation, 
which underscores the importance of the cytoskeleton for maintaining Golgi 
structure (Burkhardt, Echeverri et al. 1997).   
In addition to microtubules, Golgi structure is also maintained by a 
family of proteins containing coiled-coil motifs called golgins.  Golgins interact 
with GTPases, phospholipids, and microtubules to establish Golgi structure, 
localization, identity and vesicle tethering (Short, Haas et al. 2005).   
 
The Secretory Pathway  
The secretory pathway is the directional route through which proteins 
are synthesized in the ER, processed in the Golgi, and transported to the 
plasma membrane (Figure 1-1).  This process was first proposed by George 
Palade who followed radioactively labeled proteins through this pathway using 
biochemistry and EM autoradiography (Palade 1975).  Subsequently, yeast 
genetic manipulation was employed by Randy Scheckman to determine the 
specific protein factors (“sec” proteins) involved in each major step of the 
pathway (Novick, Field et al. 1980; Kaiser and Schekman 1990; Deshaies, 
Sanders et al. 1991).  And more recently, Jennifer Lippincott-Schwartz 
generated protein-GFP chimeras to look at the secretory pathway and its 
dynamics in real-time (Presley, Cole et al. 1997; Cole, Ellenberg et al. 1998; 
Presley, Smith et al. 1998).  These and other scientific and technological  
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Figure 1-1: A simplified depiction of the secretory and retrograde pathways.   
The organelles of the secretory pathway are shown with the ER in red, the 
ERGIC/VTC in yellow, the Golgi in green, endosomes in red, and the plasma 
membrane in black.  Lipid and protein trafficking between the organelles is 
accomplished using vesicles including the labeled COPII, COPI, AP-1 clathrin, 
and AP-2 clathrin.  Trafficking pathways using membrane tubules are shown 
with red arrows.   
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advances have shaped our current understanding of the secretory pathway 
and membrane trafficking.   
As mentioned previously, the secretory pathway begins at the ER 
where proteins are synthesized into the luminal space and correctly folded and 
modified with the help of chaperone proteins such as BiP, calnexin, and 
calreticulin.  Incorrectly folded proteins are refolded until correct (Bannykh, 
Rowe et al. 1996).  Proteins in the secretory pathway are then concentrated in 
specialized regions of the ER called ER exit sites (Bannykh, Rowe et al. 
1996).  ER exit sites contain numerous cup-like membrane outcrops that are 
surrounded by a highly structured protein coat called COPII coat (Bannykh, 
Rowe et al. 1996).  The COPII proteins form a spherical cage around 
membranes at ER exit sites encapsulating some of the membrane and the 
lumen, which is rich in secretory cargo (Mironov, Mironov et al. 2003; Gurkan, 
Stagg et al. 2006).  The result is a spherical vesicle detached from the ER 
containing various proteins and lipids destined for the secretory pathway 
(Harter and Reinhard 2000).   
The COPII coat proteins disassemble creating naked vesicles that fuse 
with each other and form a pre-Golgi organelle called the Vesicular-Tubular 
Compartment (VTC) or the ER-Golgi Intermediate Compartment (ERGIC) 
(Hauri, Kappeler et al. 2000).  How secretory proteins move through the 
different cisternae of the Golgi is still unclear. However, three hypotheses have 
been proposed.  The predominant hypothesis proposes that the ERGIC 
compartment grows and matures into a cis-Golgi cisterna, which matures into 
a medial-Golgi cisterna, which matures into a trans-Golgi cisterna until the 
cargo is transported to the plasma membrane or other destinations (Pelham 
2006).  In this maturation model, when a cisterna matures from cis-Golgi to 
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medial-Golgi, cis-Golgi proteins will be transported back in COPI coated 
vesicles and other cisternae behave similarly.  Evidence for this model comes 
from studies that localized resident Golgi processing enzymes, but not 
secretory cargo, to COPI coated vesicles (Martinez-Menarguez, Prekeris et al. 
2001).  In addition, live cell imaging reveals that individual Golgi cisternae 
rapidly convert to more mature elements by acquisition of downstream 
resident enzymes (Losev, Reinke et al. 2006; Matsuura-Tokita, Takeuchi et al. 
2006).    In contrast, a second model states that cargo, not resident Golgi 
proteins, is packaged in COPI coated vesicle and transported through the 
Golgi in a forward direction (Farquhar and Palade 1998).   Evidence for this 
model comes from studies showing that cargo molecules can be found in 
COPI vesicles (Orci, Amherdt et al. 2000).  Alternatively, a third model 
suggests that the cisternae are not as distinct as previously thought, but 
continuously connected via short membrane tubules which act to transport 
both cargo and resident enzymes using diffusion (Perinetti, Muller et al. 2009).  
While each model has evidence in support and against, it is clear that both 
COPI coated vesicle and membrane tubules are important for intra-Golgi 
transport and Golgi complex integrity.   
The TGN is where cargo is sorted for its final destination and where a 
great deal of regulation occurs.  For example, proteins to be transported to 
lysosomes are modified in the Golgi to contain a mannose-6-phosphate 
sugars (Dahms, Lobel et al. 1989).  Receptors in the TGN recognize that 
modification and sort those lysosomal enzymes into clathrin coated vesicles 
that go to endosomes and then lysosomes (Dahms, Lobel et al. 1989).  Some 
proteins and lipids are separated into lipid rafts while others contain specific 
amino acid sequences that act as zip codes for sorting (Bard and Malhotra 
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2006).  Insulin and neurotransmitters are sorted into organelles called 
secretory granules that are only secreted from the cell when a cell is signaled 
to do so (Bard and Malhotra 2006).  Insulin release is an example of this 
regulated secretion.  Constitutive secretion is the continuous sorting of cargo 
into clathrin coated vesicles at the TGN for instant release from the cell at the 
plasma membrane.   
 
Retrograde Trafficking 
Whether the Golgi complex functions using cisternal maturation or 
vesicle-mediated secretion, a reverse or retrograde pathway must exist to 
recycle resident ER enzymes and phospholipids.  Retrograde pathways also 
transport proteins and lipids from endosomes to the TGN or from the Golgi to 
the ER.  While much of the retrograde cargo is recycled receptors and 
enzymes, other proteins and infectious agents also use these routes.   
Many proteins that are transported in the retrograde direction from the 
Golgi to the ER use amino acid sequences that identify where they are to be 
located.  One example is the amino acid sequence KDEL, which is found in 
many proteins that localize primarily to the ER (Munro and Pelham 1987).  If a 
protein with the KDEL sequence escapes the ER and reaches the Golgi, it is 
recognized by a KDEL receptor, packaged into COPI coated vesicles, and 
returned to the ER (Sannerud, Saraste et al. 2003; Stornaiuolo, Lotti et al. 
2003).  Similarly, a membrane protein with a KKXX sequence will also be 
transported back to the ER (Sannerud, Saraste et al. 2003; Stornaiuolo, Lotti 
et al. 2003).  For many proteins in the secretory and retrograde pathways, 
their localization is dynamic.  While proteins with a KDEL sequence will mostly 
be in the ER, some are also present in the Golgi, but at much lower levels.  
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The ERGIC-53/p58 protein is found in the ER, the ERGIC, and the cis-Golgi 
compartments simultaneously and constantly circulates among all three (Itin, 
Schindler et al. 1995; Klumperman, Schweizer et al. 1998).  ERGIC-53/p58 
may also be transported in membrane tubules, not COPI vesicles (Hauri, 
Kappeler et al. 2000; Sannerud, Saraste et al. 2003).  To maintain the location 
of resident ER and Golgi enzymes, to recycle phospholipids and receptors, 
and to constitutively transport cargo, the retrograde and anterograde pathways 
function as two continuous countercurrents.  Thus, a challenge in cell biology 
has been to understand how an organelle can remain stable while its 
constituent molecules are constantly turning over. 
 
Membrane Vesicles  
A great deal of research has focused on how cargo is sorted into 
transport carriers, how those carriers are formed, and how they fuse with the 
correct destination.  There are three main protein coats for membrane 
vesicles.  The COPII coat contains four structural proteins; Sec13, Sec31, 
Sec23, and Sec24, which also have roles in binding specific cargo (Barlowe, 
Orci et al. 1994).  COPII vesicles transport cargo from the ER to the Golgi, and 
much of this cargo contains a specific amino acid sequence or structural motif 
that allows it to exit the ER (Aridor, Weissman et al. 1998).  Sec12 allows the 
GTPase Sar1 to bind GTP, which signals the assembly of COPII and vesicle 
budding (Spang 2008).   
In the Golgi, the COPI coat consists of α, β, β’, γ, ε, and ζ subunits.  
They assemble when the GTPase Arf1 is bound to GTP (Serafini, Orci et al. 
1991).  Although COPI vesicles may be involved in either forward transport of 
secretory cargo or reverse transport of Golgi proteins, COPI components are 
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critical for maintaining Golgi structure and function.  The final group of coated 
vesicles is clathrin coated vesicles.  Clathrin binds to various adaptor proteins 
on the TGN, endosomes, and plasma membrane (Hirst and Robinson 1998).  
Different adaptors are involved in different trafficking pathways.  Clathrin 
coated vesicles are similar to COPII and COPI because they also require 
small GTPases (Bonifacino and Glick 2004).   
In addition to coat proteins, vesicles also contain other factors including 
Rabs, tethers, and SNAREs to identify the contents and destinations of the 
vesicle.  Briefly, these proteins can act as long distance (tethers) and short 
range (SNAREs) factors that interact with partner proteins on the surface of 
organelles with which they will promote vesicle-organelle fusion.  They aid in 
matching up the correct cargo-containing vesicles with the correct organelles 
and they interact to help fuse the vesicle membrane with the target organelle 
membrane.  A vesicle containing a specific v-SNARE will partner with a t-
SNARE on the target membrane allowing the vesicle to fuse and release its 
contents (Sudhof and Rothman 2009). 
 
Membrane Tubules in Intracellular Trafficking 
Vesicles are not the only means of transporting cargo between 
organelles.  Membrane tubules are membrane extensions about 50-100 nm in 
diameter that emanate out from a donor organelle, break off, and deliver cargo 
to the acceptor organelle, or destination.  The role of tubules in organelle 
structure and function was first examined using fluorescent dyes to look at ER 
membranes in vivo, which revealed an extensive network of tubules that are 
dependent on microtubules (Terasaki, Song et al. 1984; Terasaki, Chen et al. 
1986; Dabora and Sheetz 1988).  ER membrane tubules are also dependent 
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on reticulons (Rapoport 2009).  The role of membrane tubules in Golgi 
structure and function was later seen using a small fungal metabolite brefeldin 
A (BFA), which rapidly caused tubules to form from Golgi membranes 
(Lippincott-Schwartz, Yuan et al. 1989; Orci, Tagaya et al. 1991).   These 
studies showed that Golgi membrane tubules induced by BFA are ATP-
dependent and fuse with ER membranes.  The Rothman lab and others 
showed that BFA disrupts components of the COPI coat proteins by 
preventing Arf1 nucleotide exchange (Donaldson, Finazzi et al. 1992), and 
hypothesized that constitutive trafficking pathways exist between the ER and 
the Golgi in both anterograde and retrograde directions (Orci, Tagaya et al. 
1991).   
With advances in technology, these Golgi tubules were visualized in 
real-time using fluorescently tagged proteins (Sciaky, Presley et al. 1997).  
Cargo-containing tubules were seen as predominant and ubiquitous features 
of Golgi membranes that grow and detach in a dynamic way.  These tubules 
are involved in connecting Golgi components and transporting cargo out of the 
Golgi (Sciaky, Presley et al. 1997).      Just like ER tubules, Golgi tubules 
similarly use both microtubules as a scaffold and motor proteins, but are not 
completely dependent on them to form (Sciaky, Presley et al. 1997). 
In addition to BFA, disruption of proteins involved in trafficking, 
including Sar1, causes small tubules to form at ER exit sites, and disruption of 
a TGN vesicle fission component, PKD, results in membrane tubules forming 
at the TGN (Bielli, Haney et al. 2005; Bard and Malhotra 2006; Brown, Plutner 
et al. 2008).  This indicates roles for tubules in transport and maintenance in 
the ER, the Golgi, and the TGN, and these tubules may function as a 
precursor to vesicles.   
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Membrane tubules are also involved in trafficking pathways between 
endosomes.  Endosomes are involved in the endocytosis of nutrients and 
other factors from the plasma membrane.  Once inside the cell, different 
factors are sorted and transported to other endosomes, lysosomes, or the 
TGN.  Membrane tubules are important for both endosome transport as well 
as endosome cargo sorting (Chambers, Judson et al. 2005; Bonifacino and 
Rojas 2006).  
Membrane tubule formation has also been reconstituted in vitro (Banta, 
Polizotto et al. 1995).  These studies demonstrated that membrane tubules 
can form with or without microtubules, but require cytosol and ATP (Cluett, 
Wood et al. 1993; Banta, Polizotto et al. 1995).  From in vitro and in vivo 
studies we conclude that membrane tubules are instrumental players in 
maintaining organelle structure by maintaining a reticular ER or connecting 
Golgi cisternae, and that tubules are also used to transport cargo between 
organelles.  However, while a great deal is known about the protein coats and 
regulatory facets of coated vesicles, far less is known about membrane 
tubules, including factors required for their formation and regulation.   
 
Membrane Curvature 
Both membrane vesicles and membrane tubules involved in trafficking 
require the donor membrane to change shape from a relatively flat surface to a 
highly curved sphere or tube.  There are two general ways in which a 
membrane can alter its curvature: proteins can bend the membrane 
extrinsically, and/or the phospholipids themselves can influence membrane 
shape.   In the former case, a protein can alter the shape of a membrane by a 
few methods.  First, a protein with a curved structure can interact with 
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phospholipids electrostatically and bend the membrane to fit the shape of the 
protein (McMahon and Gallop 2005).  Secondly, the protein can disrupt the 
phospholipid bilayer by inserting a hydrophobic wedge into the outer leaflet 
thereby displacing space and generating curved membranes (McMahon and 
Gallop 2005). Some examples of proteins that can manipulate membrane 
curvature are BAR-domain proteins, which have arc-shaped structure, and 
reticulons, which insert loops into the membrane (Shibata, Voss et al. 2008).   
In addition to protein factors, the phospholipids that compose a 
membrane can also influence membrane curvature.  Different phospholipids 
contain different head groups and different acyl chains.  Some phospholipid 
head groups are larger than others making the overall shape of the individual 
phospholipid less like a cylinder and more like an inverted cone.   Likewise, if a 
phospholipid is missing one of its acyl chains (a lysophospholipid), it too can 
have a more inverted cone shape.  As illustrated in Figure 1-2, altering many 
phospholipids to inverted cones can generate localized changes in membrane 
curvature where the membrane bulges outward, or forms positive curvature 
(Brown, Chambers et al. 2003).  Conversely, if a phospholipid has a small 
head group it can form negative curvature.  Lyso-phosphatidylcholine (LPC) is 
a phospholipid that can generate positive curvature whereas phosphatidic acid 
(PA) and diacylglycerol (DAG) can generate negative curvature (Brown and 
Schmidt 2005).   
For a vesicle or tubule to form from a donor membrane, positive 
curvature may be required at the site of bud/tubule formation.  Negative 
curvature may be required at the bud/tubule neck for a vesicle to bud or a 
tubule to break off from the donor membrane.  The bilayer couple hypothesis 
states that curvature of one membrane leaflet will also curve the opposite 
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leaflet (Sheetz and Singer 1974).  Lipid metabolizing enzymes may play a role 
in generating the specific phospholipids needed to generate membrane 
curvature.  Without these changes in curvature, the membrane bending 
energy will be too high for trafficking intermediates to form (Chernomordik and 
Kozlov 2005).  Two phospholipid metabolizing enzymes that are thought to be 
involved in trafficking are phospholipaseA2s (PLA2 enzymes) and 
lysophospholipid acyltransferases (LPAT) (Brown, Chambers et al. 2003).   
 
Phospholipase A2 Enzymes 
PLA2 enzymes are a diverse class of enzymes that generate 
lysophospholipids by hydrolyzing the acyl chain at the sn-2 position of a 
phospholipid (fig. 1-2).  The human genome encodes many PLA2 enzymes 
that can be either secreted out of the cell or remain in the cytoplasm 
(Murakami and Kudo 2002).  The functions of these PLA2 enzymes range from 
the release of arachidonic acid for signaling pathways to lipid degradation in 
the lysosome; however, the exact functions of most PLA2 enzymes are 
unknown (Balsinde, Winstead et al. 2002; Murakami and Kudo 2002).    The 
role of phospholipases in membrane trafficking became evident when it was 
discovered that PLA2 antagonists, including ONO-RS-082 and bromoenol 
lactone (BEL), can prevent the formation of BFA-stimulated Golgi tubules (de 
Figueiredo, Drecktrah et al. 1998).  While multiple PLA2 antagonists exhibited 
this phenotype, those specific for cytosolic calcium-independent PLA2 
enzymes were most effective.     
A unique way of stimulating and visualizing Golgi tubules without BFA is 
to use an in vitro system.  Isolated Golgi membranes incubated with bovine 
brain cytosol (BBC) will form tubules (Cluett, Wood et al. 1993; Banta,  
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Figure 1-2: Membrane curvature can be altered by phospholipid metabolizing 
enzymes.  Phospholipids can alter the relative curvature of membranes.  A 
phospholipid with two acyl or fatty acid (FA) chains has a cylindrical shape 
while phospholipids with only one FA have an inverted cone shape.  
Phospholipase A2 enzymes (PLA2) can increase inverted cone-shaped 
phospholipids while lysophospholipid acyltransferases (LPAATs) can generate 
more cylindrical-shaped phospholipids.  Both PLA2s and LPAATs have known 
antagonists, which aid in dissecting their physiological functions.   
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Polizotto et al. 1995).  PLA2 inhibitors, however, are capable of blocking these 
in vitro tubules supporting the idea that PLA2 enzymes have a critical role in 
forming Golgi membrane tubules (de Figueiredo, Polizotto et al. 1999).   
These PLA2 antagonists were also capable of blocking Golgi 
fragmentation when the microtubule depolymerizing agent nocodazole was 
applied to cells (Drecktrah and Brown 1999).  The use of these inhibitors has 
led to the conclusion that PLA2 enzymes have a role in re-forming the Golgi 
complex after mitosis, potentially by generating membrane curvature and 
membrane tubules to reconnect Golgi mini-stacks (de Figueiredo, Polizotto et 
al. 1999). PLA2 inhibitors also prevented the formation of Golgi tubules 
responsible for constitutive retrograde trafficking to the ER (de Figueiredo, 
Drecktrah et al. 2000).  These results led to the conclusions that Golgi 
membrane tubules require PLA2 activity, that Golgi membrane structure is 
mediated by both microtubules and PLA2 enzymes, and that Golgi membrane 
tubules are responsible for maintaining Golgi or ER localization of proteins 
through constitutive retrograde trafficking pathways (Brown, Chambers et al. 
2003).  We hypothesize that membrane tubules require PLA2 activity to 
generate lysophospholipids, which can form positive membrane curvature 
(Figure 1-2) – a requirement for tubule growth from the Golgi.   
 
Lysophospholipid Acyltransferases (LPATs) 
While phospholipase A2 enzymes appear to be involved in the 
formation of membrane tubules, a plethora of evidence also indicates a role for 
LPAT activity in regulating both membrane tubules and vesicles for organelle 
trafficking.  LPATs utilize the lysophospholipid products of a PLA2 reaction and 
re-acylate those substrates using acyl-CoA as a fatty acid donor to generate 
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phospholipids as shown in Figure 1-3.  Little is known about specific LPAT 
enzymes and their activity, but there are nine putative transmembrane LPAT 
proteins in the human genome that are thought to be lysophosphatidic acid 
acyltransferases or LPAATs, which is a specific kind of LPAT (Shindou, 
Hishikawa et al. 2009).  Presently they are known to be involved in de novo 
phospholipid and neutral lipid synthesis as well as a role in the Lands’ Cycle of 
phospholipid turnover (Lands 1958; Shindou, Hishikawa et al. 2009).   
LPAT activity was suspected to have a role in membrane tubules 
through the use of a weak ACAT inhibitor, CI-976, which was also found to be 
a potent LPAT inhibitor (Drecktrah, Chambers et al. 2003; Chambers and 
Brown 2004).  Drecktrah et. al. showed that CI-976 can induce the formation 
of Golgi membrane tubules in vivo and in vitro and also enhance retrograde 
trafficking to the ER (Drecktrah, Chambers et al. 2003).  If the cells are pre-
treated with a PLA2 inhibitor, subsequent treatment with CI-976 no longer 
stimulates tubules (Drecktrah, Chambers et al. 2003).  This result supports 
roles for both PLA2 and LPATs in regulating tubules.   
CI-976 not only induces Golgi tubules, but it was also shown to 
generate endosome tubules (Chambers, Judson et al. 2005).  Additionally, CI-
976 inhibits the budding of COPI and COPII coated vesicles in vitro (Brown, 
Plutner et al. 2008; Yang, Gad et al. 2008).  LPAT activity is therefore 
important for multiple steps in the trafficking pathway that involve both tubules 
and vesicles.  The phospholipids generated by LPAT activity and the 
lysophospholipids consumed by its activity also have an important role in 
regulating the membrane curvature required for tubule and vesicle biogenesis 
(Brown and Schmidt 2005).    
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Figure 1-3:  The LPAAT reaction converts a lysophosphatidic acid to 
phosphatidic acid.  A lysophosphatidic acid acyltransferase (LPAAT) will add 
an acyl-CoA or fatty acid chain to the sn-2 hydroxyl of a lysophosphatidic acid 
(LPA) to generate a phosphatidic acid (PA).  The conversion of LPA to PA is 
thought to generate net negative curvature in a membrane due to the small 
size of the PA head group shown in purple.  This reaction may involve acid-
base catalysis.  PA can also be used in the synthesis of other phospholipids 
and neutral lipids.  
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         While the effects of CI-976 indicated a prominent role for LPATs in 
membrane trafficking, no specific LPAT has been shown to have this activity in 
the Golgi.  The protein endophilin was suspected to be an LPAT and involved 
in endocytosis at the plasma membrane.  Endophilin does indeed have a 
function in endocytosis, especially at the neuronal synapse (Schmidt, Wolde et 
al. 1999; Modregger, Schmidt et al. 2003).  However, the potential LPAT 
activity of endophilin is dubious and may not be important for its function 
(Gallop, Butler et al. 2005).  A second protein, C-terminal binding 
protein3/BFA-ADP ribosylation substrate (CtBP3/BARS), was also thought to 
be an LPAT with a role in membrane trafficking (Silletta, Di Girolamo et al. 
1997; Weigert, Silletta et al. 1999).  More recently, however, it is thought that 
any LPAT activity was due to contamination by other LPATs in an in vitro 
assay (Gallop, Butler et al. 2005).  CtBP3/BARS does have an important role 
in trafficking, but mostly as a vesicle fission-inducing factor.  Although 
discredited, if CtBP3/BARS itself does not have LPAT activity, it may associate 
with other proteins in the Golgi that do (Bonazzi, Spano et al. 2005; Yang, Lee 
et al. 2005; Arstikaitis and Gauthier-Campbell 2006).   
 
Transmembrane LPAAT Family of Proteins 
Recent scientific advances including cDNA libraries and sequencing of 
the human genome have resulted in the discovery of many unknown genes 
including a family that may encode LPAATs.  It was first suspected that these 
LPAATs are involved in phospholipid metabolism due to amino acid sequence 
similarities to that of a known E. coli enzyme with acyltransferase activity 
(Coleman 1990; Coleman 1992).  Although the human proteins are much 
longer, the region of the protein sequence with similarity to the bacterial 
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protein is called the acyltransferase or plsC domain.  Other notable features of 
the primary sequence include long stretches of hydrophobic amino acids that 
may represent transmembrane regions, which are not found in the bacteria 
protein.  LPAAT orthologs can be found in bacteria (plsC), yeast (Slc4), mouse 
(AGPAT), and other higher eukaryotes.     
Within the LPAAT acyltransferase domain, there are four motifs that 
contain amino acids that are highly conserved among different LPAAT family 
members and among LPAATs of different species (Lewin, Wang et al. 1999).  
Two of these motifs are quite small while two of them are larger and contain 
acidic and basic residues.  These conserved residues may be important since 
the acyltransferase reaction may require an acidic motif to stabilize the 
hydrogen and a basic residue to stabilize the oxygen atoms that make up the 
sn-2 hydroxyl of the lysophospholipid that is being acylated (Leung 2001).  
Although this has not been empirically confirmed, it is hypothesized that an 
LPAAT would utilize an acid-base catalysis mechanism.  The first conserved 
motif has an amino acid sequence NHQSxxD, which contains both acidic 
(aspartate) and basic (histidine) residues.  The second conserved motif 
EGTRxxG also contains acidic (glutamate) and basic (arginine) residues.  
Therefore, either one of these motifs, or both, or neither could be relevant for 
catalytic activity in these LPAATs.  Some initial studies have indicated that 
these regions are important for LPAAT function in the bacterial protein 
(Morand, Patil et al. 1998).  Alternatively, conserved regions may also be 
important for substrate binding, especially if the substrates are charged 
phospholipids (Yamashita, Nakanishi et al. 2007).   
Currently, nine potential human transmembrane LPAAT proteins have 
been identified.  Most of these nine are known only by their DNA sequences, 
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but a few have been studied.  Since little is known about these LPAATs, a 
clear nomenclature scheme has not yet been established.  Originally the 
LPAATs were called AGPATs (1-acyl sn-glycerol-3-phosphate sn-2-
acyltransferases) and given greek letters based on the order in which they 
were discovered.  Since then, numbers have replaced the greek letters and, in 
some cases, more specific abbreviations have replaced the ‘LPAAT/AGPAT’ 
name as individual functions become clear.  For example, AGPAT alpha has 
been shown to be a lysophosphatidic acid acyltransferase, so it has been 
named LPAAT1.  For the sake of simplicity, in this thesis the individual family 
members will be referred to as LPAAT1-9 (Shindou and Shimizu 2009). Figure 
1-4 shows the phylogenetic relationship between the members of the LPAAT 
family. 
The first LPAAT to be cloned and studied was LPAAT1.  LPAAT1 was 
shown to be a lysophosphatidic acid acyltransferase that is expressed in all 
human tissues including the liver and pancreas, where expression is 
particularly high (Eberhardt, Gray et al. 1997).  It has also been suggested that 
LPAAT1 may catalyze a reverse reaction under conditions of excess 
phosphatidic acid (Yamashita, Kawagishi et al. 2001).  LPAAT3 also appears 
to be expressed in all tissues; however, LPAAT2, LPAAT4, LPAAT5, LPAAT8 
and LPAAT9 are expressed only in some tissues indicating that these LPAATs 
may have tissue-specific functions (Li, Yu et al. 2003; Lu, Jiang et al. 2005; 
Agarwal, Barnes et al. 2006; Agarwal, Sukumaran et al. 2007; Chen, Kuo et al. 
2008).  LPAAT2 has also been studied and found to be involved in congenital 
lipodystrophy, a condition that results in the loss of adipose tissue (Haque, 
Garg et al. 2005).  LPAAT6 may have a role in synthesizing phospholipids and 
neutral lipids in skin and mammary tissue (Beigneux, Vergnes et al. 2006;  
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Figure 1-4: Phylogeny of the nine members of the transmembrane LPAAT 
family.  Amino acid sequences for LPAAT1-9 were compared using Clustaw V 
to generate a branched diagram representing the sequence divergence.  
While some LPAATs have some sequence similarity, in general there is 
considerable variation between the nine proteins in this family of putative 
LPAATs.  
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Vergnes, Beigneux et al. 2006).  Except for the two conserved motifs, there is 
very little sequence similarity. This implies that some LPAATs may be involved 
in the de novo biosynthesis of phospholipids and neutral lipids, and that 
although multiple LPAATs are expressed in human tissues, they may have 
individual non-complementary functions.   
 
Overall Goals 
Previous work has indicated that LPAAT activity is required for the 
formation of membrane vesicles and membrane tubules for intracellular 
trafficking pathways.  Prior to the recent sequencing of LPAAT7, LPAAT8, and 
LPAAT9, the only known LPAATs were LPAAT1-6.  Since LPAAT1 and 
LPAAT2 had already been cloned and localized to ER membranes, I focused 
my efforts to identify and characterize a transmembrane LPAAT from among 
the other members that may be involved in membrane trafficking. As will be 
discussed in Chapters 2-4, I have found that LPAAT3 is a novel 
transmembrane LPAAT that is involved in Golgi trafficking and phospholipid 
metabolism.  I examined LPAAT3 using biochemical, molecular, and cell 
biological methods to investigate the regulation of Golgi structure and function.  
Additionally, the role of PLA2 activity in regulating the dynamics of membrane 
tubules in the TGN as well as trafficking from the TGN will be addressed in 
Chapter 5.  Through these two series of experiments, I show that phospholipid 
metabolism and turnover in organelle membranes is a critical feature of 
organelle structure, trafficking, and dynamics.
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CHAPTER 2 
LPAAT3, a Member of the LPAAT Family of Enzymes, is a Golgi-
Localized Lysophosphatidic Acid Acyltransferase with Two 
Transmembrane Domains 
 
Introduction 
Through the use of inhibitors such as CI-976, but no specific protein 
has been identified to perform these functions.  LPAT activity has been linked 
to de novo phospholipid metabolism and the formation of both membrane 
tubules and vesicles.    The fission-promoting CtBP/BARS and endophilin 
were suspected to have LPAT activity (Bonazzi, Spano et al. 2005), but those 
claims have since been disputed (Gallop, Butler et al. 2005).   
Previous studies from our lab suggested the presence of a CI-976-
sensitive LPAT that is very tightly associated with Golgi membranes 
(Chambers and Brown 2004).  One protein in a family of transmembrane 
LPAATs, LPAAT3, appears to co-localize with Golgi complex proteins.  In this 
chapter, the biochemical properties of LPAAT3 are explored including its 
activity and topological orientation in membranes.   LPAAT3 was tested for 
LPAT activity, substrate specificity, and specific amino acid residues required 
for activity.  Biochemical and fluorescent approaches were used to map 
transmembrane regions in the primary sequence. 
 
Materials and Methods 
Cell Culture and Immunofluorescence 
All cells were grown in MEM + 10% NuSerum (or FBS) in a 37°C 
chamber with 5% CO2.  Cells grown on coverslips were transfected with 
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pEGFP N-1 LPAAT3 and c-myc or HA epitope tags inserted into the 
sequence.  Cells were then fixed in 3.7% formalin in PBS, washed in PBS and 
permeabilized with either 0.1% Triton x-100 in PBS or a digitonin solution (3 
µg/ml digitonin, 0.3 M sucrose, 5 mM MgCl2, 120 mM KCl, 0.14 mM CaCl2, 2 
mM EGTA, 25 mM HEPES pH to 7.6 with KOH).  Cells were then incubated 
with diluted primary antibodies: 9B11 anti c-myc (1:1000), ABR anti PDI 
(1:1000), or anti HA (1:100) followed by secondary antibody anti mouse or anti 
rabbit TRITC (1:100).  Peptide antibody for LPAAT3 was designed and 
generated by Pacific Immunology (Ramona, CA). The antibody was designed 
against amino acids 254-270: CVRRFPLEDIPLDEKEA.  Cells were then 
viewed and imaged using the Zeiss Axioscope 2. 
 
Cloning/Mutagenesis 
LPAAT3 (AGPAT3) cDNA was obtained in pCMV-SPORT6 from the 
EST collection of the IMAGE Human library (Invitrogen, Carlsbad, California).  
Using PCR and the multiple cloning site of pEGFP N-1 (Clontech, Mountain 
View, CA), LPAAT3 was inserted in frame with the EGFP C-terminus before 
the stop codon.  To make the catalytic mutant of LPAAT3 and to insert either 
c-myc or HA sequences within LPAAT3, Quick Change II (Stratagene) 
mutagenesis kit with mutagenic primers was used.    All constructs were 
verified by double stranded DNA sequencing.  DNA constructs were 
transfected into cells grown on coverslips using Fugene 6 transfection reagent 
(Roche, Nutley, NJ) and processed for immunofluorescence experiments 
within 24-48 h unless otherwise indicated.   
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LPAAT Assay 
Cells were scraped from four 500 cm2 dishes at 4°C and resuspended 
in with ST homogenization buffer (0.25 M sucrose, 1 mM EDTA, and 10 mM 
Tris-Cl pH 7.4) solution such that the cell pellet was 20% of the total volume.  
Cells were lysed using a Balch-Rothman homogenizer with 22 µm clearance.  
Nuclei were removed by centrifugation at 2,000 rpm for 5 min in a clinical 
tabletop centrifuge.  Homogenized post-nuclear supernatant (PNS) aliquots 
were stored at -80°C.   
To further isolate Golgi membranes, 62% w/v sucrose solution was 
added to the PNS to a final sucrose concentration of 37% w/v.  Golgi 
membranes were enriched by flotation by overlaying the PNS with 35% 
sucrose (7 mL) and 29% sucrose (4 mL) layers (10 mM Tris, 1 mM EDTA) and 
centrifuged using an SW28.1 rotor in a Beckman Coulter Optima LE-80K 
ultracentrifuge (Beckman Coulter, Fullerton, CA) at 25,000 rpm for 2.5 h at 
4°C with no brake.  Golgi membranes were harvested from the 35%-29% 
sucrose interface and stored at -80°C.   
LPAAT assays were performed as previously described using PNS or 
isolated Golgi membranes (Drecktrah, Chambers et al. 2003; Chambers and 
Brown 2004).  Lysophospholipids (12 nmol/reaction) and 14C-palmitoyl-CoA 
(0.04 µCi/reaction) were prepared by suspending them in assay buffer (150 
mM NaCl, 1 mM EDTA, and 10 mM Tris, pH 7.4) and sonicating in a bath 
sonicator for 7 min in the dark.  PNS or Golgi (500 µg of protein) were diluted 
in 125 µl of assay buffer and warmed to 37°C.  The phospholipid mixture was 
then added to the PNS or Golgi (total volume of 200 µl) and incubated at 37°C 
for 1h.   
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To stop the reaction and extract the phospholipids, 1 mL of 
chloroform/methanol/water (316/632/53) was added to the reaction mixture so 
the final ratio of chloroform/methanol/water was 1/2/0.8 by volume.   Each 
sample was vortexed for 5 min followed by the addition of 300 µl of chloroform 
and 300 µl of water to each sample.  Each sample was vortexed again for 5 
min.  After 5 min, samples were vortexed again followed by centrifugation at 
2,000 rpm in a clinical centrifuge for 5 min.  The lower phase (approx. 600 µL) 
was removed and placed in a new tube.  The phospholipids in the lower phase 
were then dried using argon until the solution was evaporated.   
To separate samples, thin layer chromatography (TLC) plates were 
washed and dried with a chloroform/methanol/acetate/water solution 
(60/50/1/4).  The dried samples were resuspended in 10 µL of 
chloroform/methanol (1:1) and spotted onto the TLC plates.  Samples were 
resolved with the same solution used to wash the plates.  When the resolution 
buffer reached the top of the TLC plate, the plate was removed and allowed to 
dry.  To look at all phospholipids, plates were stained with a copper (II) sulfate 
solution (3% copper sulfate, 8% phosphoric acid, water) or exposed to a 
phosphor screen to detect radio-labeled lipids.  All phospholipids were from 
Avanti Polar Lipids (Alabaster, AL), chromatography reagents were from 
Alltech Chromatography (Deerfield, IL) and radiolabeled palmitoyl-CoA 
[palmitoyl-1-14C] was from PerkinElmer Life Sciences (Boston, MA).  Sample 
tubes were boro-silicate glass tubes with Teflon caps.  PNS and/or Golgi 
membranes were measured for protein concentrations using a Bradford assay.     
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Protease Protection Assay 
Cells were grown on 300 cm2 plates, scarped to harvest, and spun 
down in microcentrifuge tubes.  The pellet was resuspended in 240 µL PBS 
and homogenized by passage though a 26 2/3 gauge syringe.  Nuclei were 
pelleted from the homogenate by microcentrifugation at 600 X g.  The 
supernatant was collected and microsomes, Golgi and other membranes were 
further pelleted by centrifugation at 100,000 x g for 30 min.  The pellet was 
resuspended in 240 µL PBS and to this was added 2 µg/ml trypsin and 0.1% 
Triton X-100 when appropriate (Stone, Levin et al. 2006). 
 
Statistics 
Error bars on graph represent standard deviation values for a minimum 
of three hundred cells counted and a minimum of three independent 
experiments. 
 
Results 
LPAAT3 Partially Localizes to Golgi Membranes 
To identify a transmembrane LPAAT that would be a candidate for 
regulating Golgi structure and function, LPAAT3, LPAAT4, LPAAT5, and 
LPAAT6 were cloned into GFP expression vectors.  Each construct contained 
a GFP fused to the C-terminus of the protein.  As shown in Figure 2-1, 
LPAAT3 appeared to co-localized with an antibody marker for the Golgi 
complex, LPAAT5 co-localized with a marker for mitochondria, and LPAAT4 
and LPAAT6 co-localized with antibody markers for the ER.  This initial screen 
indicated that LPAAT3 may be functioning at the Golgi membranes.  To verify 
these results, a more comprehensive analysis was done.  First, an antibody  
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Figure 2-1: The localization of LPAAT3, 4, 5, and 6-GFP to organelle markers.  
LPAAT3, 4, 5, and 6 were fused with green fluorescent protein (GFP) and 
compared to markers for different organelles.  LPAAT3-GFP localized with 
Golgi markers, LPAAT5-GFP localized with mitochondria markers, and 
LPAAT4 and 6 localized with ER markers.   
 34 
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Figure 2-2: LPAAT3 Localization.  (a) An antibody raised against LPAAT3 co-
localized with the cis-Golgi marker 10E6.  (b) HeLa cells were generated to 
stably express LPAAT3-GFP.  HeLa cells and HeLa cells expressing LPAAT3-
GFP were incubated with antibodies to the ER marker Protein Disulfide 
Isomerase (PDI), the cis-Golgi protein 10E6, the medial-Golgi protein 
Mannosidase II (ManII), and the trans-Golgi protein Galactosyltransferase 
(GalT).  LPAAT3 co-localized with all of the Golgi markers.   
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generated against human LPAAT3 was incubated with cells to locate 
endogenous LPAAT3.  In Figure 2-2a, the LPAAT3 antibody co-localized with 
the cis-Golgi marker 10E6.  Both HeLa cells and Clone 9 cells (rat 
hepatocytes) were transfected with LPAAT3-GFP and selected for individual 
cells stably expressing the recombinant protein.  In both cell lines, LPAAT3 
was located in the Golgi membranes.  Using those LPAAT3-GFP HeLa cells, 
different markers for the cis-Golgi, the medial-Golgi, and the trans-Golgi were 
compared to LPAAT3-GFP.  Those markers all localized with LPAAT3 (Figure 
2-2b).   
 
LPAAT3 Primary Sequence and Domains 
LPAAT3 therefore may be a source of LPAAT activity which has been 
shown to be important for Golgi trafficking.  Human LPAAT3 is expressed in 
multiple tissues including the liver, brain, heart, lung and spleen (Lu, Jiang et 
al. 2005).  More recently, LPAAT3 has been implicated in multiple activities 
within testicular cells including roles in phosphatidic acid and 
phosphatidylinositol metabolism (Yuki, Shindou et al. 2009).  To further 
examine LPAAT3 and the transmembrane LPAAT family, in silico methods 
were used to conduct primary sequence analysis.  Figure 2-2 shows the 
relationship between LPAAT3 among higher eukaryotes including the 
previously mentioned conserved motifs (blue boxes) and the putative 
transmembrane regions (black arrows).  While the LPAAT family is quite 
diverse (Fig. 1-4), LPAAT3 itself is conserved among higher eukaryotes.  The 
simplified domain structure of LPAAT3 is shown in Figure 2-4 including 
potential transmembrane domains and the acyltransferase domain.  Two  
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Figure 2-3 LPAAT3 Sequence Alignment.  The primary amino acid sequences 
for multiple eukaryotes were aligned using Clustaw V.  LPAAT3 is highly 
conserved between species.  Black arrows indicate potential transmembrane 
regions.  Horizontal blue boxes indicate two conserved consensus motifs 
found in all LPAAT3 sequences, all LPAAT family members, E. coli PlsC, and 
S. cerevisiae SLC4 orthologs.   
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Figure 2-4: LPAAT domains.  Like other LPAATs, LPAAT3 is predicted to 
contain transmembrane (TM) domains and an acyltransferase or PLsC 
domain.  Within the PLsC domain, two conserved motifs are shown that 
contain acidic and basic amino acid residues.  Amino acids mutated to 
alanines are shown in bold.   
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highly conserved amino acid motifs within the acyltransferase domain are 
shown in bold type. 
 
LPAAT3 is a Lysophosphatidic Acid Acyltransferase (LPAAT) 
To determine if LPAAT3 is indeed an acyltransferase and to determine 
its substrate specificity, PNS from cells overexpressing LPAAT3 were 
incubated with various lysophospholipids and a 14C-palmitoyl-CoA fatty acid.  
LPAAT3 is expected to transfer the radiolabeled palmitoyl-CoA to a  
lysophospholipid acceptor to generate a phospholipid.  The products can then 
be resolved using thin layer chromatography to separate and detect 
radioactive phospholipid products.   
After quantification, a two-fold increase in the amount of radioactive 
phosphatidic acid (PA) was seen in cells overexpressing LPAAT3, but not in 
mock transfected cells (Figure 2-5).  Radiolabeled phosphatidylcholine (PC) 
was the most abundant, as expected, but its levels did not change in cells 
overexpressing LPAAT3.  Other phospholipids including 
lysophosphatidylserine (LPS), lysophosphatidylethanolamine (LPE), and 
lysophosphotidylcholine (LPC) showed no significant change between 
transfected and untransfected cells (Figure 2-5).  Cells expressing LPAAT6, a 
known LPAAT, were also assayed as a positive control for LPAAT activity.  
From these data, it appears that LPAAT3 is in fact an LPAAT and uses 
lysophosphatidic acid as a substrate for its acyltransferase activity. 
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Figure 2-5:  Measuring the acyltransferase activity of LPAAT3.  PNS from 
control cells and cells overexpressing either LPAAT3 or LPAAT6 were 
incubated with C14 radio-labeled palmitoyl-CoA and lyso-phospholipid 
substrates in vitro.  Both LPAAT3 and LPAAT6 appeared to have 
lysophosphatidic acid acyltransferase activity (LPA-AT).  There were no 
changes between control PNS and transfected lysates for 
lysophosphatidylcholine (LPC), lysophosphatidylethanolamine (LPE), or 
lysophosphatidylserine (LPS) acyltransferase activity.  
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Figure 2-6:  LPAAT activity in Golgi from cells overexpressing LPAAT3.  Golgi 
membrane from control cells and cell overexpressing LPAAT3 were isolated 
by sucrose gradient high-speed centrifugation.  Golgi from cells with LPAAT3 
have elevated LPA-AT activity when compared to control.   
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Cells Overexpressing LPAAT3 have elevated LPAAT activity in Golgi 
Membranes 
Since LPAAT3 partially localizes to Golgi membranes, changes in 
LPAAT activity was tested in Golgi membranes from cells transfected with 
LPAAT3.  For this purpose, Golgi membranes were further separated from 
PNS by sucrose gradient centrifugation.  Additionally, only endogenous 
lysophospholipids were made available as potential acceptors of the 14C-
palmitoyl CoA.  Golgi membranes from cells overexpressing LPAAT3 had 
higher levels of LPAAT activity compared to untransfected cells (Figure 2-6).  
These data indicate that not only is LPAAT3 partially located in Golgi 
membranes, but it can also alter the phospholipid makeup of the membrane by 
increasing the amounts of phosphatidic acid and decreasing the amounts of 
lysophosphatidic acid.   
 
Mutagenesis of Two Conserved Motifs can abolish LPAAT activity in 
LPAAT3 
Within the acyltransferase domain of LPAAT3 there are two motifs 
common to all LPAAT family members (Figure 2-4).  These motifs are 
suspected to be important for catalysis and substrate binding.  The 
acyltransferase reaction may be an acid-base catalysis.  Using site-directed 
mutagenesis, critical conserved amino acids including acidic and basic 
residues were changed to alanines.  Within the first motif, NHNFEID was 
changed to NAAFEIA and within the second motif, CEGTR was changed to 
CAATR. This mutant form of LPAAT3 was tested for LPAAT activity. 
In Figure 2-7, Golgi membranes from cells transiently overexpressing 
either LPAAT3 wild type (WT) or LPAAT3 mutant (MT) are compared to mock  
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Figure 2-7:  Identification of amino acid motifs in LPAAT3 critical for LPAAT 
activity.  Acidic and basic residues in the acyltransferase domain of LPAAT3 
were mutated.  Golgi membranes from cells transiently transfected with this 
mutant version were compared to Golgi membranes from cells with LPAAT3 
wild type (WT) and from control cells.  Unlike the wild type, the LPAAT3 
mutant (MT) did not have elevated LPA-AT activity.    Cells stably expressing 
LPAAT3 (ST) also were shown to have an increase in LPA-AT activity, 
although less than transiently transfected cells.  Activity has been normalized 
to protein concentration and expression levels of LPAAT3 WT and LPAAT3 
MT.
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transfected cells for their LPAAT activity using endogenous lysophospholipid 
acceptors.  While there was a greater than 1.5 fold increase in LPAAT activity 
for LPAAT3 WT, there was little change from mock transfected cells for the 
LPAAT3 MT Golgi.  The Golgi membranes from cells stably expressing 
LPAAT3 (ST) were also assayed for LPAAT activity, and indeed showed an 
increase in acyltransferase activity, albeit less robust than transiently 
transfected cells.  These data show that at least one, and possibly two, 
conserved motifs within the acytransferase domain are important for catalytic 
activity and that cells with stably expressed LPAAT3 are viable.  Stably 
expressing cells and a catalytically dead version of LPAAT3 will be useful in 
dissecting the physiological functions of LPAAT3. 
 
Identification of Transmembrane Regions Using Selective Membrane 
Permeability and Immunofluorescence 
Human LPAAT3 and other LPAAT family members are all thought to be 
transmembrane proteins; however, each LPAAT is predicted to have varying 
numbers of transmembrane regions and varying locations for those regions.  
The location of transmembrane regions has implications for positioning the 
acyltransferase domain in the luminal or on the cytoplasmic side of the 
membrane bilayer and may therefore have an effect on the physiological roles 
of LPAAT3.  Analysis of the primary sequence of LPAAT3 by various computer 
algorithms predicts a variable number and location of putative transmembrane 
domains.  These predictions do not allow us to make any definitive 
conclusions about the topology of LPAAT3; however the potential locations of 
these transmembrane regions are depicted in Figure 2-4.  To empirically 
determine which sequences of LPAAT3 are exposed to the cytoplasm and 
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which are inside the lumen, a method developed by Jennifer Lippincott-
Schwartz using antibody recognition of epitopes was used (Lorenz, Hailey et 
al. 2006).   
Specific amino acid sequences that are easily recognized by common 
antibodies were inserted into the wild type amino acid sequence of LPAAT3.  
The sequences used include c-myc and HA epitopes and GFP.  The first two 
are short and unlikely to disrupt membrane insertion or folding and the last is 
known to leave LPAAT3 functional if fused to the C-terminus.  Cells 
transfected with LPAAT3 DNA containing each of these sequences were 
selectively permeabilized in either a digitonin solution or a Triton X-100 
solution.  At the detergent concentrations used, digitonin permeabilizes only 
the plasma membrane, thus allowing antibodies to enter the cell and bind to 
sequences exposed to the cytoplasm.  Triton X-100 solution permeabilizes all 
membranes and thus exposes all sequences to antibodies whether inside the 
lumen or in the cytoplasm.   
In Figure 2-8, it appears as though the regions around myc11, myc41, 
HA93, and GFP367 are all exposed to the cytoplasm since they were 
identified by antibody binding and secondary fluorescent antibody when 
incubated with digitonin (see Fig. 4-10 for tag locations).  The regions around 
myc175, however, were not exposed in the cytoplasm and therefore were in 
the lumen.  These results predict two possible transmembrane passes in the 
sequence of LPAAT3.  Protein disulfide isomease (PDI) is a resident ER 
protein in the lumen, which was used as a control. 
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Figure 2-8:  The use of immunofluorescence to determine the membrane 
topology of LPAAT3.  Epitope tags were inserted into the LPAAT3 amino acid 
sequences at specific locations indicated by the tag and number.  These were 
individually transfected into HeLa cells and the cells were permeabilized with 
either digitonin or Triton X-100 and treated with corresponding antibodies.  
Cells that showed fluorescence with digitonin processing are inferred to 
contain that epitope tag in the cytoplasm.  If cells are not fluorescent with 
digitonin, the tag is inferred to reside in the lumen.   
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Figure 2-9: Protease protection assay to determine LPAAT3 topology.  
Organelles from cells transfected with LPAAT3 genes encoding epitope tags 
were isolated and subjected to trypsin proteolysis.  Epitope were detected by 
western blot.  In samples with Triton X-100 all tags are expected to be 
digested, in samples with digitonin only cytosolic tags are expected to be 
digested, and in samples with no trypsin tags are expected to be preserved.  
Lanes 1 and 2 are duplicates, and lanes 3 and 4 are also duplicates.   
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Identification of Transmembrane Regions by Protease Protection Assay 
The protease protection assay is the same fundamental idea as above, 
except that instead of testing for exposed regions using antibodies in vivo, 
exposed areas were subjected to proteolysis in vitro.  I used two methods to 
determine the topology of LPAAT3 to give confidence in the final model. In-tact 
Golgi and microsomes from cells transfected with each of the constructs 
described above were incubated with trypsin or trypsin and Triton X-100.  If 
the epitope is not detected by western blot analysis, then it is presumed to be 
exposed to the cytoplasm and digested. If a strong band is detected, then the 
membrane is protecting that sequence from proteolysis.  The results indicate 
that myc11, myc41, HA93, and GFP367 are all digested by trypsin and 
myc175 is not (Fig. 2-9).  These data are consistent with the fluorescence data 
and give us a model of LPAAT3 including the number of transmembrane 
regions and, along with hydrophobic domain information, the approximate 
locations of these regions (Fig. 2-10).   
 
Discussion 
The effects of the inhibitor drug CI-976 suggested the importance of 
LPAT activity in membrane trafficking events including tubule formation, 
vesicle formation, and Golgi structure maintenance (Drecktrah, Chambers et 
al. 2003; Chambers and Brown 2004; Brown, Plutner et al. 2008; Yang, Gad et 
al. 2008).  Here, a  transmembrane LPAAT, LPAAT3, was identified based on 
its sequence, cloned into mammalian expression vectors, and found to be 
localized to Golgi membranes.  LPAAT3 is the first Golgi LPAAT to be 
characterized.  Its localization to all regions of the Golgi may indicate a role in 
membrane trafficking.   
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Since little is known about LPAAT3, biochemical analyses were done 
including testing for enzymatic activity, substrate specificity, important catalytic 
residues, and topology.  LPAAT3 has LPAAT activity, which increases the 
amount of PA in membranes.  PA has recently been implicated in multiple 
trafficking events including the formation of COPI coated vesicles (Yang, Gad 
et al. 2008).  COPI vesicles require acyl-CoA as a co-factor for budding, but 
the function of the acyl group has been enigmatic (Glick and Rothman 1987; 
Pfanner, Orci et al. 1989).  Perhaps the acyl-CoA is used by an LPAAT 
enzyme.  Although PA is thought to be important for membrane curvature and 
trafficking, PA can also be a precursor of diacylglycerol (DAG), which can also 
generate curvature and has similarly been implicated in membrane trafficking 
from the Golgi and the TGN (Kooijman, Chupin et al. 2005; Fernandez-
Ulibarri, Vilella et al. 2007; Asp, Kartberg et al. 2009).  In this study, a 
catalytically inactive form of LPAAT3 was also generated, providing strong 
evidence for an acid-base catalysis mechanism for LPAAT3.   
Based on empirical results, the numbers and locations of 
transmembrane regions were mapped for LPAAT3 in Figure 2-10.  We predict 
the first conserved motif, NHNFEID to by cytoplasmic while the second motif 
CEGTR is luminal.  Since both of these conserved motifs contain acidic and 
basic amino acid residues we cannot confidently conclude if LPAAT3 
metabolizes phospholipids on the cytoplasmic leaflet of the membrane or the 
luminal leaflet of the membrane.  Although having the two motifs on opposite 
sides of the membrane was not expected and is quite puzzling, recent data for 
LPAAT1 topology and activity indicate that LPAAT1 has a similar topology and 
motif positioning (Yamashita, Nakanishi et al. 2007).  In the case of LPAAT1, 
disruption of either one of the two suspected catalytic motifs completely  
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Figure 2-10: Model for LPAAT3 topology.  Based on independent methods for 
determining membrane topology, it has been demonstrated that LPAAT3 
contains two transmembrane domains.  The second transmembrane domain 
bisects the acyltransferase domains and places each of the conserved 
catalytic motifs on opposing sides of the membrane.  Shown in the diagram 
are the two conserved motifs that are important for catalytic activity and the 
locations of epitope tags inserted into LPAAT3 for topology determination.   
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abolishes activity.  We hypothesize that LPAAT3 may require both motifs for 
either catalysis or substrate binding.  LPAAT3 may also have activities on both 
sides of the membrane such as transferring acyl groups from one leaflet to the 
other.  While the N-terminus of LPAAT3 maps to the cytosolic side of the 
membrane using these assays, we cannot rule out the possibility that a 
hydrophobic area within this domain may insert into the membrane, but not as 
a transmembrane segment.    
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CHAPTER 3 
The Role of LPAAT3 in Maintaining Golgi Structure 
 
 
Introduction 
Proteins that alter the phospholipid makeup of membranes have not 
only been implicated in membrane trafficking, but also in the maintenance of 
organelle structure and morphology.  For example, overexpression or 
knockdown of specific phospholipase A2 enzymes has been shown to 
fragment the Golgi (Bechler et. al., unpublished data).  Additionally, the use of 
PLA2 inhibitors like ONO-Rs-082 (ONO) have been shown to cause the Golgi 
to fragment (de Figueiredo, Polizotto et al. 1999).  Golgi membrane tubules 
are believed to have multiple functions: to form membrane transport 
compartments and to form membrane bridges between different parts of the 
Golgi (de Figueiredo, Polizotto et al. 1999).  Since PLA2 enzymes have a role 
in forming Golgi tubules, altering their expression levels or inhibiting them with 
a drug disrupts the tubules that keep the Golgi connected. 
Inhibition of LPATs with CI-976 causes the Golgi to redistribute the ER, 
so no changes in Golgi structure could be observed (Drecktrah, Chambers et 
al. 2003).  However, the fact that CI-976 induces Golgi membrane tubules 
implies a role for LPATs in membrane tubule formation.  These same tubules 
may be important for the maintenance of Golgi architecture.  LPAAT3 can alter 
Golgi membrane phospholipid content and may also be involved in tubule 
formation.  Therefore, LPAAT3 may also have a role in maintaining Golgi 
structure.  In this chapter I will present experiments designed to test this 
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hypothesis by analyzing the effects of overexpression and reduced expression 
of LPAAT3 on Golgi morphology.   
 
Materials and Methods 
Reagents and Antibodies 
ONO-RS-082 (ONO) was purchased from BioMol (Plymouth Meeting, 
PA) and stored in ethanol at 10 mM.  The antibody GPP130 (1:1000) was a 
gift from Adam Linstead (Carnegie Mellon, Pittsburg), hMannII (1:1000) was a 
gift from Kelly Moreman (Univ. Georgia, Athens), and 10E6 (1:100) and M6PR 
were previously characterized (Cluett 1993, Brown 1987).  All electron 
microscopy reagents and materials were purchased from EMS (Hatfield, PA).   
 
Immunofluorescence and knockdown 
For ONO experiments, HeLa cells were grown on coverslips, washed 
three times in MEM without serum and incubated with 10 µM ONO for 30 min.  
For immunofluorescence, cells were processed as previously described in 
Chapter 2.  For knockdown experiments, HeLa cells were grown on 35 mm 
dishes and transfected with a cocktail of siRNAs designed against LPAAT3 
from Dharmacon (Lafayette, CO) using the RNAi MAX transfection kit 
(Invitrogen, Carlsbad, California) for 72 h.  The following siRNA sequences 
were transfected with their antisense compliments:  
GAGACCAAGCACCGCGUUAUU, CGUCUUUGCCAGCGGAUCAUU, 
GCUCCAAGGUCCUGCUAAUU, and GGAAAUAGAAUGACGGGAAUU.  
Cells were cultured and transfected as described in Chapter 2.   
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Transmission Electron Microscopy of Thin Sections 
Cells were fixed in the dish using glutaraldehyde/osmium tetroxide 
combination fixative for 2 h (Hirsch and Fedorko 1968).  Cells were washed 
three time for 15 min in 0.1 M sodium cacodylate then stained with 0.25% 
uranyl acetate for 30 min.  Cells were dehydrated using 70%, 95%, and 100% 
ethanol washes and then removed from the culture dish with propylene oxide.  
Cells were pelleted in a microcentrifuge and infiltrated with 1:1 propylene oxide 
and Spurrs for 30 min.  The supernatant was removed and replaced with 
100% Spurrs overnight.  The Spurs was replaced twice more and polymerized 
at 60°C for 24 h. The polymerized block was sectioned and stained with lead 
citrate and uranyl acetate.  Images were taken using FEI/Philips Morgagni 
TEM.   
 
Statistics 
Error bars on graph represent standard deviation values for a minimum 
of three hundred cells counted and a minimum of three independent 
experiments. 
 
Results 
LPAAT3 Overexpression Prevents Golgi Breakup by ONO  
ONO is a reversible PLA2 inhibitor that has been shown to block the 
formation of tubules (de Figueiredo, Polizotto et al. 1999).  Cells incubated 
with ONO do not form BFA-stimulated tubules in vivo and isolated Golgi 
membranes do not form tubules in vitro.  ONO also causes the Golgi to form 
multiple mini-stacks instead of the usual compact ribbon structure (de 
Figueiredo, Polizotto et al. 1999).   
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Figure 3-1:  The effects of LPAAT3 expression on ONO-induced Golgi 
fragmentation.  (a) Cells transfected with LPAAT3 wild type (WT) or LPAAT3 
mutant (MT) were treated with 10 µM of the PLA2 inhibitor ONO for 30 min.  
Golgi membranes were examined using trans-Golgi marker GPP130.  All the 
Golgi membranes appeared fragmented except in cells overexpressing 
LPAAT3 WT.  (b)  Quantification of fluorescence results confirms that LPAAT3 
WT protects the Golgi against ONO-mediated fragmentation.   
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Figure 3-2:  Measuring LPAAT3 knockdown by western blot analysis.  (a) A 
mixture of four siRNA molecules that bind to LPAAT3 mRNA was transfected 
into cells stably expressing LPAAT3-GFP.  Cell lysates were then examined 
by western blot analysis using antibodies against the resident Golgi enzyme 
mannosidase II (120 kD) as a loading control and against GFP to determine 
LPAAT-GFP (72 kD) levels.  (b) The bands for LPAAT3-GFP were quantified 
and indicate that siRNA transfection can reduce overall levels of LPAAT3 by 
80-90%. 
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To see if LPAAT3 has any effect on Golgi structure, cells were transfected with 
LPAAT3 WT and treated with or without 10 µM ONO for 30 min.  At that time 
nearly all of the untransfected control cells showed fragmented Golgi ribbons; 
however, cells expressing LPAAT3 WT had mostly compact Golgi ribbons 
(Figure 3-1).  Additionally, cells overexpressing the catalytic mutant form of 
LPAAT3, LPAAT3 MT, showed similar Golgi fragmentation to the control cells 
(Figure 3-1).  This implies that overexpression of LPAAT3 and the production 
of PA in Golgi membranes can compensate for PLA2 inhibition, supporting the 
idea that phospholipids have an important role in determining and maintaining 
organelle structure. 
 
Knockdown of LPAAT3 Causes Golgi Fragmentation 
Since overexpression of LPAAT3 has a protective effect against agents 
that induce Golgi fragmentation, I tested the effects of reduced expression of 
LPAAT3, or knockdown, on Golgi morphology.  To knockdown LPAAT3, a 
cocktail of small interfering RNA molecules (siRNA) was transfected into cells 
stably expressing a GFP-tagged LPAAT3.  Cells no longer expressing GFP 
were assumed to be knocked down for LPAAT3.  Additionally, lysates from 
cells knocked down for LPAAT3 were tested by western blot for the levels of 
LPAAT3.  As shown in Figure 3-2, the siRNA cocktail reduced LPAAT3 levels 
by 80%.  Importantly, reduced expression of LPAAT3 did not have an effect on 
Golgi proteins because levels of Mann II were unchanged. 
Immunofluorescence of the Golgi complex in cells knocked down for 
LPAAT3 showed that the Golgi was fragmented into multiple puncta (Figure 3-
3).  Mock transfected and LPAAT3 transfected cells had a Golgi fragmentation 
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index value of only 10%, while cells knocked down for LPAAT3 had a value of 
90% (Figure 3-3b).    
 
LPAAT3 Knockdown Fragments All Golgi Cisternae into Mini-Stacks 
Golgi membranes can fragment in different ways.  One possibility is for 
different cisternae to separate, thereby generating clusters of cis-Golgi, 
clusters of medial-Golgi, clusters of trans-Golgi, and clusters of TGN.  
Alternatively, fragments can contain elements of each cisterna in the Golgi 
making each fragment a miniature Golgi stack or “mini-stack.”   
After siRNA-mediated knockdown of LPAAT3, cells were processed for 
immunofluorescence against proteins known to be found in different regions of 
the Golgi.  Each of the Golgi cisternae including the cis, medial, and TGN were 
observed to be fragmented (Figure 3-4a).  This strongly indicated that the 
fragments formed from LPAAT3 knockdown are Golgi mini-stacks.  Further 
evidence was seen using transmission electron microscopy of thin sections 
from cells knocked down for LPAAT3.  In these cells there are multiple Golgi 
stacks throughout the cytoplasm of the cell (Figure 3-4b).  Control cells 
typically had only one or two Golgi stacks located centrally in the cells 
adjacent to the nucleus.   
 
Discussion 
Although many cellular components are involved in maintaining Golgi 
morphology and structure, little is known about the role of phospholipids 
themselves in maintaining the stacked and centralized structure.  Many of the 
factors that disrupt Golgi structure are also involved in proper Golgi functions  
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Figure 3-3:  Golgi complex fragmentation by LPAAT3 knockdown.  (a) HeLa 
cells stably expressing LPAAT3-GFP were transfected with siRNA molecules 
targeting LPAAT3 mRNA.  In cells with reduced GFP fluorescence, LPAAT3 
was presumed knockdown.  These cells contained fragmented Golgi.  (b) 
Quantification verified that LPAAT3 knockdown dramatically increases the 
Golgi fragmentation index. 
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Figure 3-4:  LPAAT3 knockdown results in Golgi mini-stacks.  (a)  Cells 
knockdown for LPAAT3 have Golgi fragments that contain proteins normally 
found in the cis-Golgi (10E6), the medial-Golgi (ManII), and the Trans Golgi 
Network (M6PR).  (b) Electron micrographs of LPAAT3 knockdown cells 
contain multiple in-tact Golgi stacks indicating that the Golgi fragments 
observed by fluorescence are mini-stacks. 
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such as the regulation of secretion and the modification of newly synthesized 
proteins.   
As shown in Chapter 2, LPAAT3 generates PA and uses LPA in the 
Golgi membranes of a cell.  Overexpression or knockdown of LPAAT3 causes 
the phospholipid make-up of the membrane to change.  This appears to have 
a profound effect on the morphology and the overall structure of the Golgi.  
Overexpression protects the Golgi from fragmentation-inducing agents such 
as ONO while knockdown causes fragmentation into Golgi mini-stacks.  
Knockdown of LPAAT3 may allow PLA2 enzymes to produce excess 
lysophospholipids (LPL).  These LPLs are thought to produce membrane 
tubules, and excessive tubules could fragment the Golgi.  If LPAAT3 has an 
effect on Golgi structure, it may also have an effect on Golgi function, 
specifically membrane trafficking from the Golgi to the ER and trafficking out of 
the Golgi to the plasma membrane.   
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CHAPTER 4 
LPAAT3 has a Role in Membrane Tubule Formation and Golgi Trafficking 
 
Introduction 
Phospholipid-modifying enzymes including PLA2 enzymes and LPAATs 
have been shown to either positively promote the formation of membrane 
tubules or negatively regulate their formation, respectively (Brown, Chambers 
et al. 2003).  This was discovered using inhibitors against those two classes of 
enzymes.  The PLA2 inhibitors ONO and BEL (HELSS) prevent Golgi tubules 
from forming in vitro and in vivo (de Figueiredo, Drecktrah et al. 1998).  Those 
inhibitors can also prevent Golgi tubules from forming when cells are treated 
with the fungal metabolite brefeldin A (BFA).  BFA has been shown to rapidly 
cause the Golgi to tubulate and redistribute enzymes and lipids to the ER.  
Another antagonist that also results in Golgi tubules is the LPAT inhibitor CI-
976 (Drecktrah, Chambers et al. 2003).  This pharmacological agent revealed 
how important LPAATs are for trafficking and was the impetus to study 
LPAATs.   
Membrane tubules are not only formed in the presence of BFA and CI-
976; they are involved in the constitutive recycling of many proteins that 
escape the ER.  One protein that continuously cycles between the ER and the 
Golgi in tubules is the ERGIC53/p58 receptor protein, which is involved in the 
trafficking of glycosylated proteins (Klumperman, Schweizer et al. 1998).  
ERGIC-53/p58 is therefore a useful tool for observing the bidirectional 
transport pathways that exist between the ER and the Golgi.    A very useful in 
vitro Golgi tubulation assay has been developed that only requires isolated 
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Golgi membranes and a preparation of bovine brain cytosol (BBC) to induce 
tubules outside of the cellular environment (Banta, Polizotto et al. 1995).   
While CI-976 has shown the importance for LPATs and Golgi tubules in 
ER to Golgi (Brown, Plutner et al. 2008) and Golgi to ER transport (Drecktrah, 
Chambers et al. 2003), less is known about anterograde trafficking from the 
Golgi to the plasma membrane.  Since CI-976 results in the Golgi 
redistributing back to the ER, the LPAAT antagonist has only limited use for 
studying trafficking from the Golgi or TGN to the plasma membrane.  Since 
LPAAT3 is partially localized to the Golgi, has LPAAT activity, and has an 
effect on Golgi structure, it may also have a role in Golgi trafficking.  Here I 
examine Golgi trafficking, in vivo and in vitro as well as retrograde and 
anterograde trafficking under the conditions of LPAAT3 overexpression or 
knockdown.   
 
Materials and Methods 
Transfection and Immunofluorescence 
The following antibodies were used:  GPP130 was used at 1:1000 
dilution, ERGIC-53 was used at 1:100 dilution, and β-COP was used at 1:50 
dilution. Cells were transfected with pEDsRed N-1 ts045 VSV-G, pEGFP N-1 
ssHRP-FLAG, pEGFP N-1 LPAAT3 Wild Type, pEFGP N-1 LPAAT3 Mutant, 
and pEGFP N-1 LPAAT6 Wild type using Fugene 6 (Roche).  LPAAT3 was 
knocked down as described in Chapter 3.   
Tissue culture cells were grown and maintained as described in 
Chapter 2.  For BFA experiments, cells were washed with MEM (no serum) 
and treated with 5 µg/ml BFA in DMSO at either 37°C or 24°C.  For CI-976 
experiments, cells were washed with MEM (no serum) and treated with 50 µM 
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CI-976 in DMSO.  For ERGIC-53 trafficking, cells were shifted to a 15°C water 
bath for 3 h then quickly warmed by changing the medium to 37°C.  For ts045 
VSV-G experiments, cells were incubated at 40°C for 18 h and then shifted to 
32°C.  Coverslips containing cells were fixed and processed for 
immunofluorescence as described in Chapter 3.    
 
VSVG/ssHRP 
Cells were transfected with pEGFP N-1 ssHRP-Flag for 24 h.  Cell 
medium was removed and the cells were washed three times and replaced 
with fresh media.  To sample HRP activity in the media, 50 µL of media was 
removed from the culture dishes for every time point and to measure non-
secreted HRP activity, the cells were scraped from the dishes, incubated in 
PBS +1% NP-40 for 10 min, and centrifuged at max speed to remove cell 
debris.  For each sample, 10 µL was incubated with 50 µL of TMB reagent 
(Sigma, St. Louis, MO).  When samples turned blue, 50 µL of 1 M HCl was 
added to stop the reaction.  All reactions were done in duplicate and measured 
using the SpectraMax 190 (Molecular Devices, Sunnyvale, CA) 96-well plate 
reader at 450 nm.   To measure ts045 VSV-G DsRed localization, 100 images 
from fixed cells were processed using ImageJ (NIH) to measure the pixel 
intensity in the Golgi and total cell regions of interest (ROI).  Background 
values of pixel intensity per unit area were measured and subtracted from 
each ROI. 
 
Sholl Analysis 
A modified Sholl analysis (Sholl 1953) was performed to quantify the 
number and length of Golgi membrane tubules in cells expressing 
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fluorescence Golgi markers.  Digital micrographs were traced in NIH ImageJ 
and the intersections of those tubules with concentric circles were determined 
using the Sholl software plug-in.  These values were used to determine the 
number of tubules at each particular length. 
 
In vitro tubulation  
Golgi complexes were enriched as indicated above.  Isolated membranes 
(Chapter 2) were incubated with either 1.4 mg/ml BBC or 1.4 mg/ml BSA in 
tubulation buffer (0.1 mM ATP, 50 mM KCl, 1 mM MgCl2, 25 mM Tris-Cl, 10 
mM HEPES, pH 7.4)  for 15 min at 37°C.  Bovine brain cytosol (BBC) was 
prepared as described previously (Banta, Polizotto et al. 1995).  Reactions 
were placed on ice and then on 300 mesh copper EM grids coated with 
Formvar and carbon.  Golgi membranes were negatively stained with 2% 
phosphotungstic acid (pH 7.2) viewed using the Morgagni 286 electron 
microscope, and quantified as tubulated or not tubulated.   
 
Results 
LPAAT3 Overexpression Slows, and Knockdown Accelerates the 
Kinetics of Golgi to ER Retrograde Trafficking  
 
The Effects of LPAAT3 Expression on BFA Tubules and Retrograde 
Trafficking 
Since the LPAT inhibitor CI-976 causes Golgi membranes to form 
membrane tubules, overexpression of an LPAAT is expected to have a 
negative impact on membrane tubule biogenesis.  Membrane tubules are 
sometimes difficult to observe under normal conditions.  Therefore, BFA was 
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used to induce rapid tubule formation.  HeLa cells and cells transfected with 
either LPAAT3 WT, LPAAT3 MT, LPAAT3 knockdown, or LPAAT6 as a control 
were treated with BFA for various time points and then fixed and stained for 
Golgi markers (Figure 4-1).  It was observed that cells transfected with 
LPAAT3 did not readily form Golgi tubules and took longer to fuse with the ER.  
Conversely, cells knocked down for LPAAT3 formed tubules much faster, and 
the Golgi fused with the ER very quickly.  Tubules formed so quickly that the 
experiment was repeated at 24°C instead of the usual 37°C to slow the 
process down so LPAAT3 knockdown cells could be fixed and counted; 
however, the results were the same (Fig. 4-1c).    
Figure 4-1c shows that the Golgi in cells knocked down for LPAAT3 
formed tubules faster and fused with the ER faster than controls and that cells 
overexpressing LPAAT3 WT formed tubules much more slowly.  Cells with 
compact Golgi, tubulated Golgi, or diffuse Golgi/ER were quantified (not 
shown).  The t ½ for each condition was calculated and shown in Figure 4-1b 
and 4-1c for cells incubated at 37°C and 24°C respectively.  For cells 
overexpressing LPAAT3 and treated with BFA at 37°C, the Golgi took twice as 
long to go from a compact Golgi to diffuse ER while the LPAAT6 and LPAAT3 
MT was similar to control cells.  A similar result was seen at 24°C.  
Conversely, LPAAT3 knockdown cells were 35% faster than control cells.   
This may indicate a role for LPAAT3 expression and membrane tubule 
formation.   
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Figure 4-1:  The effects of LPAAT3 expression on BFA-stimulated Golgi 
tubules.  (a) Control cells or cells transfected with LPAAT3 wild type (WT), 
LPAAT3 mutant (MT), LPAAT6, or LPAAT3 siRNA were treated with 10 µg/ml 
brefeldin A (BFA) for various lengths of time at either 37°C.  (b) At 37°C 
LPAAT3 WT, but not the others, slowed the formation of BFA-stimulated 
tubules and retrograde trafficking as measured by the time it took for the Golgi 
to become diffuse.  (c) At 24°C, LPAAT3 knockdown cells were faster at 
forming BFA-stimulated Golgi tubules and retrograde trafficking.  Knockdown 
cells were done at 24°C because tubules formed too quickly at 37°C to 
quantify. 
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The Effects of LPAAT3 Expression on CI-976-Induced Golgi Tubules 
Although BFA is useful for looking at Golgi membrane tubules, it 
disrupts other trafficking components.  Figure 4-2 shows that cells treated with 
BFA have less COPI coat protein located on Golgi membranes as expected.  
Although LPAAT3 expression levels did not effect β-COP (Figure 4-2) or Arf1 
(not shown) on the Golgi, there may be other unforeseen consequences of 
using BFA.  To address this, CI-976 was also used to generate Golgi 
membrane tubules.   
CI-976 is an LPAT inhibitor and only alters phospholipid metabolism 
without disrupting other trafficking components.  Because CI-976 inhibits a 
BFA-independent pathway, it is useful for testing the effects of LPAAT3 
expression on Golgi tubules.  Figure 4-3 shows images of cells treated with CI-
976 and demonstrates how cells overexpressing LPAAT3 do not form tubules 
as quickly as control cells and LPAAT3 MT cells.  In contrast, cells knocked 
down for LPAAT3 form those tubules much faster.  The graph in Figure 4-3b 
shows the rate of Golgi to ER retrograde transport in the cells treated with CI-
976. 
 
The Effects of LPAAT3 Expression on ERGIC-53/p58 Trafficking 
One last means of measuring Golgi to ER transport is to use a system 
that is independent of both pharmacological agents and transfected markers.  
For this, the endogenous ERGIC-53/p58 was used to monitor Golgi to ER 
transport.  ERGIC-53/p58 is a transport receptor that is located in the ER and 
the early Golgi compartment called the ERGIC (Klumperman, Schweizer et al. 
1998).  ERGIC-53/p58 exits the ER in COPII coated vesicles with secretory 
cargo and returns in Golgi tubules.  A useful feature is that at 15°C,  
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Figure 4-2:  Dissociation of Arf1 and β-COP by short-term BFA treatment.  In 
HeLa cells, LPAAT3-GFP stable cells, LPAAT3-GFP wild type (WT) 
transfected cells, and LPAAT3-GFP mutant (MT) transfected cells, the COPI 
coat protein β-COP remained associated with the Golgi membranes.  After 
BFA was added for 2 min to all cells, β-COP became cytoplasmic with no 
change to LPAAT3 localization. 
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Figure 4-3:  The effects of LPAAT3 expression on CI-976-stimulated Golgi 
tubules. (a) Cells transfected with LPAAT3-GFP wild type (WT), LPAAT3-GFP 
mutant (MT), LPAAT3 siRNA, and control cells were treated with 50 µM CI-
976 for various amounts of time.  Cells overexpressing LPAAT3-GFP WT were 
slower to form Golgi tubules than control and LPAAT3-GFP MT 
overexpressing cells, while cells knocked down for LPAAT3 were faster at 
forming Golgi tubules.  (b) Quantification of a time course of CI-976 treatment 
of cells overexpressing LPAAT3 compared to cells knockdown for LPAAT3.  
Cells were scored for the Golgi marker GPP130 becoming diffuse/ER. 
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ERGIC53/p58 is able to exit the ER, but not return, so it accumulates in the 
ERGIC compartment until the temperature is changed.  Shifting back to 37°C 
results in a near-synchronous wave of ERGIC53/p58 transport from the cis-
Golgi to the ER via membrane tubules (Itin, Schindler et al. 1995; 
Klumperman, Schweizer et al. 1998).   
Cells expressing LPAAT3 WT or knocked down for LPAAT3 were 
incubated at 15°C, shifted to 37°C and fixed to observe the rate of ERGIC to 
ER trafficking (Figure 4-4a).  After only two minutes, 60% of the ERGIC-53 
protein was back to the ER in LPAAT3 knockdown cells while in control cells 
only 40% had returned.  In cells overexpressing LPAAT3, less then 10% had 
returned (Figure 4-4b).  These data, taken together with the BFA and CI-976 
observations, indicate that overexpression of LPAAT3 significantly slows 
membrane tubule-mediated retrograde trafficking.  In contrast, knockdown of 
LPAAT3 has the opposite effect and accelerates the rate of retrograde 
trafficking.   
 
LPAAT3 Expression Effects Anterograde Trafficking from the TGN to the 
Plasma Membrane 
Membrane tubules and vesicles are also involved in anterograde 
transport from the Golgi, specifically from the TGN (Bard and Malhotra 2006).  
Historically, the vesicular stomatitis virus G protein (VSV-G) has been used as 
a marker for transport through the secretory pathway.  Cells overexpressing 
LPAAT3 or knocked down for LPAAT3 were co- transfected with ts045 VSV-
G-DsRed.  At 40°C ts045 VSV-G-DsRed cannot properly fold and remains 
trapped in the ER (Fig. 4-5).  After the cells were shifted to 32°C, the ts045 
VSV-G-DsRed folded and was transported to the Golgi as expected.   
 88 
 
 
 
 
 
 
 
Figure 4-4:  ERGIC-53/p58 retrograde trafficking and LPAAT3 expression.  (a) 
Clone 9 rat hepatocytes, Clone 9 cells stably expressing LPAAT-GFP, and 
Clone 9 cells transfected with LPAAT3 siRNA were incubated at 15°C for 3 h 
to accumulate the ERGIC-53/p58 protein in the cis-Golgi.  Cells were then 
warmed to 37°C to allow retrograde trafficking of ERGIC-53/p58.  Cells with 
LPAAT3-GFP maintained the cis-Golgi localization of ERGIC-53/p58 as shown 
by immunofluorescence.  Cells knocked down for LPAAT3 rapidly transported 
ERGIC-53/p58 to the ER compared to control.  Quantification of cells with ER-
localized ERGIC-53/p58 at 2 min (b) and 5 min (c) showed that ERGIC-53/p58 
arrived at the ER faster in knockdown cells and slower in LPAAT3-GFP cells.   
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Figure 4-5:  LPAAT3 expression and ts045 VSV-G-DsRed trafficking from the 
TGN to the cell surface.  (a) HeLa cells overexpressing LPAAT3-GFP WT or 
knocked down for LPAAT3 were transfected with ts045 VSV-G-DsRed and 
incubated at 40°C for 18 h.  Cells were then shifted to 32°C for various lengths 
of time.  The VSV-G protein easily arrived at the Golgi in all cells, but only 
efficiently trafficked to the cell surface in control cells.  (b) By measuring the 
fluorescence in the Golgi and comparing that to total cell fluorescence, cells 
either overexpressing or knocked down for LPAAT3 were shown to be 
deficient in ts045 VSV-G-DsRed trafficking out of the Golgi.   
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Figure 4-6:  Secretion of ssHRP is altered by LPAAT3 expression.  Cells 
expressing LPAAT3-GFP wild type (WT), LPAAT3-GFP mutant (MT), LPAAT3 
siRNA, and control cells were transfected with an ssHRP-FLAG expression 
vector.  ssHRP was made in the ER, transported to the extracellular space, 
and measured by taking media samples.  LPAAT3 knockdown cells secreted 
ssHRP twice as fast as control cells and LPAAT3 MT cells while LPAAT3 wild 
type cells were much slower.   
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However, at later time points when the ts045 VSV-G-DsRed was expected to 
transport from the Golgi to the plasma membrane, accumulation of ts045 VSV-
G-DsRed was seen in cells overexpressing LPAAT3 and knockdown for 
LPAAT3 (Figure 4-5a).  The percent of fluorescence in the Golgi was 
compared to total fluorescence in Figure 4-5b to quantify TGN to plasma 
membrane transport.   
While the transmembrane VSV-G is packaged into tubules at the TGN, 
soluble cargo can exit the Golgi through multiple pathways (Bard and Malhotra 
2006).  A secretable form of horseradish peroxidase (ssHRP) is a soluble 
protein that uses the secretory pathway and is easily detectable by enzymatic 
assay once released from the cell.    Cells expressing ssHRP were tested to 
see if LPAAT3 expression has any effect on secretion.  ssHRP in the 
extracellular media were collected and measured after various time points.  
Cells overexpressing LPAAT3 were slower at secreting ssHRP while cells 
knocked down for LPAAT3 were much faster (Figure 4-6).  LPAAT3 MT had 
little effect on ssHRP secretion.  Both VSV-G and ssHRP anterograde 
trafficking appear to be affected by LPAAT3, which implies a role for LPAAT3 
and phosphatidic acid in both retrograde and anterograde Golgi trafficking.   
 
LPAAT3 Negatively Regulates Golgi Membrane Tubule Biogenesis 
The Golgi complex transports proteins to the ER through the retrograde 
pathway and to the plasma membrane through the anterograde pathway, but 
the actual transport cargo can be sorted into either coated vesicles or 
membrane tubules (Bard and Malhotra 2006).  Many of the transport pathways 
discussed so far, including BFA-induced, ERGIC-53, and VSV-G, use 
membrane tubules, so LPAAT3 may be involved in regulating membrane 
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tubule formation.  Images from cells in the BFA assays were re-examined for 
the rate of Golgi to ER transport and for the extent of Golgi membrane tubules.  
The Sholl analysis, which has been used previously to measure dendrite 
branching in neurons (Sholl 1953), was applied to these images as a means of 
measuring both the number and length of Golgi membrane tubules.  Figure 4-
7a shows that cells overexpressing LPAAT3 have far fewer tubules when 
treated with BFA compared to control cells.  Also, those tubules are far shorter 
than those in control cells (Figure 4-7b).  This novel method for quantification 
was useful for determining the extent of Golgi tubules in these cells. 
Another approach for looking at Golgi tubules is an in vitro method.  
Here, cells stably expressing LPAAT3 were processed to isolate Golgi 
membranes.  These Golgi membranes were incubated with bovine brain 
cytosol (BBC), which has been shown to induce tubules in a PLA2-dependent 
manner (Cluett, Wood et al. 1993; de Figueiredo, Drecktrah et al. 1998).  
Many more of the Golgi membranes from control cells formed tubules in vitro 
compared to those from LPAAT3 overexpressing cells (Figure 4-8).  These 
data indicate that LPAAT3 negatively regulates Golgi membrane tubule 
formation.    
Membrane tubules may either function independently as transport 
carriers for cargo, or may act as a membranous scaffold for vesicle formation.  
To test if LPAAT3 has a role in the formation of vesicles as well as membrane 
tubules, an in vitro COPI budding assay was used.  Golgi membranes were 
incubated with rat liver cytosol and allowed to form COPI vesicles, which were 
separated by sucrose-gradients and high-speed centrifugation.  Figure 4-9 
shows that these assays have high variability and that only a slight decrease  
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Figure 4-7:  Golgi tubule number and length is altered by LPAAT3 
overexpression.  Control cells and cells overexpressing LPAAT3-GFP wild 
type were treated with 10 µg/mL BFA for various lengths of time.  Images of 
the cells were then processed using the Sholl Analysis to measure membrane 
tubule length and number.  (a) Cells overexpressing LPAAT3 had fewer Golgi 
tubules, especially at early time points following BFA addition.  (b)  Moreover, 
cells overexpressing LPAAT3 also have shorter membrane tubules.  The Sholl 
Analyses were aided by the efforts of Griselda Yvone, a former undergraduate 
in the lab.   
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Figure 4-8:  In vitro tubulation assay.  (a) Golgi membranes were extracted 
from HeLa cells and HeLa cells stably expressing LPAAT3.  These Golgi 
membranes were then incubated with 1.6 mg/mL bovine brain cytosol (BBC) 
to stimulate membrane tubule formation.  (b)  LPAAT3 Golgi formed far fewer 
tubules than control Golgi.   
 99 
 100 
in COPI vesicles was observed in cells stably expressing LPAAT3 versus 
control cells.   
 
Discussion 
The LPAT inhibitor CI-976 inhibits the formation of COPI and COPII 
coated vesicles and rapidly causes the Golgi to form membrane tubules which 
redistribute the Golgi to the ER (Drecktrah, Chambers et al. 2003; Brown and 
Schmidt 2005; Brown, Plutner et al. 2008; Yang, Gad et al. 2008).  This 
implies that LPAAT proteins may have roles in multiple membrane trafficking 
events by altering relative amounts of lysophospholipids and phospholipids.  
Here I examined the potential roles of LPAAT3 in Golgi membrane trafficking 
by overexpressing LPAAT3 or by knocking down expression of LPAAT3.   
Overexpression of LPAAT3 slowed retrograde Golgi to ER trafficking 
when membrane tubules were stimulated by the addition of BFA or CI-976.  
Furthermore ERGIC to ER trafficking was also slowed for the endogenous 
protein ERGIC-53/p58.  Additionally, knocking down LPAAT3 had the opposite 
effect and accelerated retrograde transport.  The fact the LPAAT3 catalytic 
mutant had little effect on the kinetics of Golgi to ER transport implies that the 
LPAAT activity of LPAAT3 is critical for these phenotypes and that the 
phospholipids in the membrane are therefore important factors in the formation 
of transport intermediates.   
LPAAT3 overexpression also slowed anterograde transport of both 
VSV-G (transmembrane) and ssHRP (soluble) cargo proteins.  Cells knocked 
down for LPAAT3 have accelerated anterograde trafficking for ssHRP, 
although it is still unclear why VSV-G transport was not accelerated.  One 
hypothesis is that VSV-G is transmembrane cargo and is transported from the  
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Figure 4-9:  In vitro COPI vesicle budding assay.  Golgi membranes from 
HeLa cells and cells stably expressing LPAAT3 were incubated with rat liver 
cytosol at 37°C to produce vesicles and 4°C as a control.  Golgi membranes 
and vesicles were then separated by sucrose-gradient high-speed 
centrifugation and quantified by western blot against the mannoside II protein.  
(a) The relative number of vesicles formed by control cells and cells 
expressing LPAAT3 are about the same.   
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TGN to the basolateral region of the plasma membrane while ssHRP is 
soluble, and therefore can be transported more freely to any region of the 
plasma membrane.  Cells knocked down for LPAAT3 may accelerate one 
pathway (soluble/apical) while slowing another (transmembrane/basolateral).     
The Sholl Analysis, the in vitro tubulation assay, and the COPI budding 
assay indicate specific roles for LPAAT3 in negatively regulating Golgi 
membrane tubules.  These data support previously published data regarding 
PLA2 enzymes and tubule biogenesis as well as data from CI-976 
experiments.  Without LPAAT activity in the Golgi, membrane tubules may 
form without regulation, and therefore cause changes to Golgi morphology and 
the rate of Golgi trafficking.  If Golgi trafficking is too fast, proteins may not be 
properly modified before exiting the Golgi and may be transported to the 
wrong destination.  Conversely, if trafficking is too slow, like in cells 
overexpressing LPAAT3, cell growth can be diminished since new membrane 
cannot quickly arrive at the plasma membrane.  Cell migration and efficient 
protein synthesis may also be adversely affected.     
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CHAPTER 5 
The Role of Phospholipase A2 Activity in Trafficking from the Trans Golgi 
Network (TGN) to the Plasma Membrane 
 
Introduction  
Cargo exiting the TGN is targeted to the basolateral or apical plasma 
membrane, and is concentrated in coated vesicles or membrane tubules.  
Some protein cargo, including VSV-G and collagen, is found mainly in TGN-
derived  membrane tubules (Hirschberg, Miller et al. 1998; Polishchuk, Di 
Pentima et al. 2003).  The mechanisms of how cargo is sorted into either 
tubules or coated vesicles, and how that cargo is targeted to endosomes or 
the plasma membrane, is largely unknown.  The current model for TGN tubule 
formation is that membrane domains in the TGN become enriched in transport 
cargo, but exclude resident TGN proteins (Bard and Malhotra 2006).  
Membrane tubules are pulled from these domains with the help of kinesin, and 
then undergo fission (Polishchuk, Di Pentima et al. 2003).  Some of the factors 
involved in fission include heterotrimeric G proteins and protein kinase D 
(PKD) (Yeaman, Ayala et al. 2004; Diaz Anel and Malhotra 2005).  When 
overexpressed, the kinase inactive form of PKD (PKD-KD) leads to an 
extensive network of tubules forming from the TGN, but not the Golgi, which 
are thought to form as a result of fission inhibition (Liljedahl, Maeda et al. 
2001; Maeda, Beznoussenko et al. 2001).   
Fission of TGN secretory membrane tubules requires many factors 
including the phospholipids within the membrane itself.  The metabolism of 
phosphatidic acid (PA), diacylglycerol (DAG), and phosphotidylinositol (PI) is 
thought to have roles in tubule fission (Bard and Malhotra 2006).  PKD itself 
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binds to DAG, which may act as a binding domain for the fission machinery 
(Maeda, Beznoussenko et al. 2001; Baron and Malhotra 2002).  Phospholipids 
are also thought to generate unstable domains within the membrane that 
promote hemi-fission and eventual membrane fission by altering the curvature 
and physical properties of the membrane itself (Bard and Malhotra 2006).  
Although a great deal is known about how TGN transport carriers separate 
from the donor membrane, little is known about how these extensive TGN 
tubules form.  Previous studies have suggested that phospholipids are 
important in regulating membrane tubule formation as well as tubule fission 
(Brown, Chambers et al. 2003).  
Phospholipase A2 (PLA2) enzymes generate lysophospholipids from 
phospholipids in cellular membranes (Brown, Chambers et al. 2003).  PLA2 
enzymes have been shown to have a role in the formation of Golgi retrograde 
tubules, intra-Golgi tubules, and recycling endosome tubules both in vivo and 
in vitro (de Figueiredo, Drecktrah et al. 1998; de Figueiredo, Drecktrah et al. 
2000; de Figueiredo, Doody et al. 2001; Brown, Chambers et al. 2003).  PLA2 
enzymes increase lysophospholipids which have more positive curvature on 
the cytosolic leaflet of the membrane; a process which may be necessary for 
membrane tubules to emanate from organelles.  Since PLA2 enzymes have 
been linked to membrane tubules in other organelles, PLA2 enzymes may also 
have a role in forming membrane tubule transport carriers at the TGN.   
 Here I used a pharmacological approach to examine the role of PLA2 
enzymes in the formation of membrane tubules at the TGN through the use of 
specific inhibitors.  The TGN tubules formed by PKD-KD were used as a tool 
to visualize the effects of these PLA2 antagonists.  Here I show that TGN 
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tubules require PLA2 enzymes upstream of PKD in the biogenesis of TGN 
tubules, and that these tubules are important for post-Golgi trafficking.     
 
Methods and Materials 
DNA Constructs 
PKD-KD-GST and ssHRP-FLAG were both generous gifts from Dr. Vivek 
Malhotra.  PKD-KD was cut from the parent vector with SmaI and SalI and 
ligated into pEGFP-C1 (Clontech, Mountain View, CA) to generate PKD-KD-
GFP.  ts045 VSVG-YFP was a generous gift from Dr. Brian Storrie and was 
cut from the parent vector using BamHI and XhoI   and ligated into pEDsRed 
N-1 (Clontech, Mountain View, CA).  All cell culture, ONO treatments, ssHRP 
assays, and VSV-G assays were done as previously described in Chapters 2, 
3, and 4.   
 
Results 
PKD-KD-Induced TGN Tubules are inhibited by PLA2 Antagonists 
 
PLA2 enzymes have been implicated in multiple membrane trafficking 
events, specifically those involving the formation of membrane tubules or 
pleiomorphic membrane transport carriers.  The TGN has been shown to form 
clathrin-coated vesicles, membrane tubules, and vesicular-tubular clusters 
(VTC) that transport secretory cargo to the plasma membrane and 
endosomes.  I tested if the PLA2 inhibitor ONO has a role in the formation of 
these transport carriers.  The kinase dead form of PKD (PKD-KD) is known for 
generating dramatic and abundant TGN tubules, which are thought to result 
from the impediment of membrane tubule fission.  Cells transfected with PKD-
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KD-GFP were shown to have numerous TGN membrane tubules, but cells 
treated with ONO did not (Figure 5-1a).  Fewer cells contained TGN tubules as 
early as 15 min after ONO addition, and by 90 min almost no cells contained 
tubules (Figure 5-1b).   
To test if TGN tubule inhibition is concentration-dependent, various 
concentrations of ONO were added to cells for 30 min and the number of cells 
with TGN tubules quantified (Figure 5-2).  As the concentration of ONO 
increased, the number of cells with TGN tubules decreased and plateaued at 
20 µM. A second cytoplasmic PLA2 antagonist, BEL, was also tested for its 
ability to induce changes in TGN tubules.  At 10 µM, BEL effectively inhibited 
TGN tubules generated by PKD-KD as well (Figure 5-3).  Similar to ONO, the 
number of cells with TGN tubules was quantified and showed that BEL 
significantly diminished the number of cells with TGN tubules after 15 min.    
 
PLA2 Activity is Required for the Formation of TGN Tubules 
 
BEL is a suicide substrate and therefore irreversible, but ONO is 
reversible (de Figueiredo, Drecktrah et al. 1998).  Cells transfected with PKD-
KD were treated with ONO for 60 min to ensure that nearly all cells lacked 
TGN tubules.  When cells were washed free of ONO, tubules reformed at the 
TGN within minutes (Figure 5-4).  Taken together, these data show that the 
PLA2 antagonists ONO and BEL appear to have a direct role in TGN tubules 
that contain the fission machinery PKD.   
Although ONO decreases the number of cells containing PKD-KD TGN 
tubules, the fate of those pre-existing tubules after addition of ONO is unclear.  
The tubules may break off from the TGN or retract.  Since PKD-KD inhibits  
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Figure 5-1:  The effects of ONO on PKD-KD TGN tubules. HeLa cells 
transfected with PKD-KD-GFP were incubated with 10 µM ONO-Rs-082 or a 
solvent control for various periods of time.  (a) Within 30 min, cells without 
ONO had abundant TGN tubules containing PKD-KD-GFP while in cells 
treated with ONO for 30 min, few cells contained tubules. (b)  Cells were 
counted as containing TGN tubules, or not for each time point.   
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Figure 5-2:  Inhibition of TGN tubule formation is ONO concentration-
dependent. HeLa cells transfected with PKD-KD-GFP were treated with 0, 2.5, 
5, 10, 20, and 30 µM ONO for 30 min.  The number of cells with TGN tubules 
was counted. 
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fission, the latter hypothesis is favored.  To determine the fate of TGN tubules 
after the addition of ONO, live cell imaging was used to follow existing tubules.  
Figure 5-5 shows that the TGN tubules containing PKD-KD are very dynamic 
and are in a constant state of extension and retraction, as well as breaking 
away from the TGN.  In cells treated with ONO, tubules either break off or 
retract, but they are not replaced with new tubules.  This implies a role for 
PLA2 enzymes in the formation, but not necessarily the maintenance or 
fission, of tubules. 
 
Constitutive TGN-to-Plasma Membrane Trafficking Requires PLA2 
Activity   
Although PLA2 antagonists clearly inhibit TGN membrane tubules 
generated by PKD-KD, their effect on constitutive export is not known.  To see 
if ONO blocks all TGN transport, a secreted form of horseradish peroxidase 
(ssHRP) was used to monitor secretion.  Cells expressing PKD-KD have been 
shown previously to slow, although not completely block, the secretion of 
ssHRP.   We found that cells treated with ONO were significantly inhibited in 
ssHRP secretion, even more so than PKD-KD (Figure 5-6).  As expected, cells 
with both PKD-KD and ONO had no significant secretion.  These results 
indicate an important role for PLA2 enzymes in generating constitutive TGN 
transport carriers. 
While the transport and secretion of ssHRP is constant throughout the 
secretory pathway, ONO could inhibit transport of ssHRP at multiple stages 
along the secretory pathway, not just for the TGN.  Therefore, we employed 
the temperature sensitive vesicular stomatitis virus G protein (ts045 VSV-G) 
which can be monitored at individual trafficking steps including ER-to-Golgi  
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Figure 5-3:  BEL inhibition of PKD-KD TGN tubules. HeLa cells transfected 
with PKD-KD-GFP were treated with 10 µM BEL (HELSS) for 0, 15, 30, 60, 
and 90 min.  The number of cells containing TGN tubules were counted.   
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Figure 5-4:  ONO washout allows TGN tubules to reform. HeLa cells 
transfected with PKD-KD-GFP were treated with 10 µM ONO for 60 min.  The 
media was then replaced without ONO.  (a) Within 15 min of ONO washout, 
the TGN reformed tubules which became more numerous and extensive after 
30 and 60 min.  (b)  Cells were counted for containing TGN tubules at various 
time points after ONO washout.  After 60 min, nearly all cells contained 
tubules.   
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Figure 5-5:  Live cell imaging of cells expressing PKD-KD-GFP.  (a) In 
untreated cells, membrane tubules are dynamic in that they form, retract, and 
break off.  (b) In cells treated with 10 µM ONO, membrane tubules similarly 
retract and break off, but do not re-form.  Red arrows and yellow triangles 
indicate, respectively, forming/growing or retracting membrane tubules. 
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and TGN-to-plasma membrane.  I used the 40°C temperature block to 
accumulate ts045 VSV-G-DsRed in the ER for 18 h, and then I shifted the 
cells to 20°C for 3 h to accumulate the protein in the TGN.  Transfected cells 
were then shifted to the permissive temperature of 32°C to allow the ts045 
VSV-G-DsRed to be transported to the plasma membrane.  Both control cells 
and cells treated with ONO showed an accumulation of VSV-G in the TGN at 
20°C.  However, 60 min following the shift to 32°C, only control cells efficiently 
transported VSV-G to the plasma membrane (Figure 5-7).  Cells treated with 
ONO retained VSV-G in the TGN at similar levels seen before the temperature 
shift.    Control cells also contained many TGN tubules with VSV-G, while 
ONO-treated cells did not have any tubules (not shown).  This strongly 
indicates a role for PLA2 enzymes in generating transport carriers at the TGN.     
 
Discussion 
Membrane trafficking from the TGN to the plasma membrane is a 
critical step in the secretory pathway.  Hirschberg et al showed that many 
proteins, including VSV-G, are transported out of the TGN in membrane 
tubules that break off from the donor organelle (Hirschberg, Miller et al. 1998).  
These tubules are particularly suited for large proteins such as collagen that 
cannot fit into small 60 nm coated vesicles.  Recently, both PKD and BARS-50 
have been implicated in the fission of these tubules.  However, very little in 
known about how the tubules are formed (Bard and Malhotra 2006).   
Previous studies have indicated that PLA2 enzymes are important for 
membrane tubule biogenesis.  PLA2 enzymes are important for BFA-
stimulated Golgi membrane tubule formation as well as constitutive retrograde 
Golgi tubule formation (de Figueiredo, Drecktrah et al. 2000).  PLA2 enzymes  
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Figure 5-6: ONO blocks TGN trafficking of ssHRP. HeLa cells were 
transfected with empty vector or PKD-KD-GFP for 24 hours followed by 
transfection with ssHRP-FLAG for 24 hours.  Cells media was replaced and 
media samples were taken at 2, 4, 6, and 8 hours.  Cells treated with 10 µM 
ONO had complete inhibition of ssHRP secretion and cells overexpressing 
PKD-KD-GFP had approximately 50% reduction in secretion.   
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Figure 5-7:  ONO block TGN trafficking of VSV-G ts045-DsRed. Cells 
transfected with Ts045 VSV-G-DsRed were incubated at 40 °C for 18 hours 
then 20 °C for 3 hours and then permissive temperature of 32 °C.  (a) Cells 
without ONO readily transported VSV-G to the plasma membrane within 60 
min at permissive temperature while cells treated with 10 µM ONO retained 
VSV-G in the TGN.  (b) TGN-localized VSV-G was quantified by measuring 
fluorescence intensity of DsRed in the TGN versus the entire cell.  Numbers 
were normalized to control and demonstrate that ONO blocked Ts045 VSV-G-
DsRed escape from the TGN. 
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are also critical for generating tubular bridges that connect Golgi stacks 
(Brown, Chambers et al. 2003).  This study adds to our understanding of PLA2 
enzymes in trafficking.  
Here I show that the PLA2 antagonist ONO can inhibit TGN tubules 
induced by the overexpression of PKD-KD.  The effect is concentration-
dependent as well as reversible.  In addition, ONO also blocks TGN to plasma 
membrane transport of both soluble cargo (ssHRP) and transmembrane cargo 
(VSV-G).   
Using live cell imaging, I observed the dynamics of TGN tubules 
generated by PKD-KD for the first time.  These tubules are very dynamic and 
constantly grow and retract.  I believe that ONO has little effect on existing 
tubules, but prevents the formation of new tubules.  This is supported by the 
fact that washing out ONO caused the rapid formation of new TGN tubules; 
moreover, VSV-G was never seen in tubules when cells were treated with 
ONO, but VSV-G containing tubules were plentiful in control cells.   
A second PLA2 antagonist, BEL, also inhibited TGN tubules.  ONO is a 
cPLA2 inhibitor with an IC50 of 10 µM, however, BEL inhibits Ca2+-
independent-PLA2 enzymes (iPLA2 enzymes) at 1 µM and Ca2+-dependent-
PLA2 enzymes (cPLA2 enzymes) at 10 µM (de Figueiredo, Drecktrah et al. 
1998).  Little effect was seen when BEL was used at 1 µM (not shown), but 
membrane tubules were inhibited at 10 µM.  This implies that a cPLA2 may be 
responsible for the formation of TGN tubules.  Evidence now exists for both 
iPLA2 enzymes and cPLA2 enzymes in membrane trafficking.   
Here I have shown that PLA2 activity is critical for export from the TGN.  
We hypothesize that PLA2 enzymes generate lysophospholipids (LPLs) with 
large head groups and a fatty acid.  An accumulation of LPLs may be able to 
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alter the membrane from a flat surface to a curved membrane, since LPLs are 
shaped like inverted cones, while cylindrical phospholipids do not.  This 
change in membrane morphology may be critical for forming the shape of a 
membrane tubule, or the binding of proteins.  Phospholipids appear to have 
key roles not only in the scission of transport carriers, but also in their 
formation.    
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CHAPTER 6 
Conclusions 
 
The role of LPAAT activity in membrane trafficking was first suspected 
through the use of the LPAAT antagonist CI-976.  This inhibitor was an 
extremely useful tool for looking at the role of LPAATs in the formation of 
membrane tubules and vesicles and how LPAATs impact specific trafficking 
pathways. One shortcoming was that no specific LPAAT had been identified 
as a potential target of CI-976.  Since the CI-976-sensitive LPAAT activity was 
tightly associated with the Golgi membranes, and could not be stripped away 
by high concentrations of salt, transmembrane LPAATs were explored as 
potential CI-976 targets (Chambers and Brown 2004).  LPAAT3 is one of 
many transmembrane LPAATs identified by sequence alone, and was found to 
be localized to Golgi and ER membranes.   
I performed a biochemical analysis of LPAAT3 which showed that 
LPAAT3 used lysophosphatidic acid (LPA) and acyl-CoA substrates to make 
phosphatidic acid (PA).  This activity is located in the Golgi membranes 
themselves indicating that overexpression of LPAAT3 can increase PA levels 
in the membrane.  This conversion between LPA and PA can alter membrane 
curvature, which is important for membrane trafficking and organelle structure.  
LPAAT3 indeed has an effect on Golgi membrane structure.  I found that 
overexpression of LPAAT3 appears to preserve the compact structure against 
fragmenting agents such as ONO.  Conversely, when I knocked down 
LPAAT3, the Golgi fragmented into individual mini-stacks that could be seen 
using electron microscopy.  This implies that phospholipid metabolism has a  
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Figure 6-1: Model for PLA2s and LPAATs in forming tubules.  (a)  PLA2s and 
LPAATs may have antagonistic roles where PLA2s form membrane tubules 
and LPAATs retract tubules.  (b)  Alternatively, PLA2s may form membrane 
tubules which are then consumed by LPAATs in a more cooperative 
mechanism.     
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role in maintaining Golgi complex structure.  I investigated the structure of 
LPAAT3 and generated a model for LPAAT3 topology, which places critical 
domains on both the cytoplasmic and luminal sides of the membrane.  The 
exact purpose of this is unclear, but both cytoplasmic and luminal loops are 
important for LPAAT catalytic activity.  My topology model for LPAAT3 is 
similar to one recently reported for LPAAT1 (Yamashita, Nakanishi et al. 
2007). 
Next, I examined LPAAT3 for a potential role in membrane trafficking.  
Overexpression of LPAAT3 and knockdown of LPAAT3 proved to be useful 
tools in understanding the role of LPAATs and phospholipids in Golgi 
trafficking.  Cells overexpressing LPAAT3 were much slower to form Golgi 
tubules when stimulated with either BFA or CI-976.  LPAAT3 also slowed the 
Golgi to ER retrograde trafficking of endogenous ERGIC-53/p58.  A 
catalytically dead mutant of LPAAT3, however, had no effect.  These results 
support previous observations that inhibition of LPAATs can promote tubules.  
LPAAT3 knockdown accelerated Golgi tubule formation and retrograde 
trafficking.  While neither overexpression nor knockdown of LPAAT3 caused a 
complete defect in Golgi trafficking, phospholipid metabolism is redundant and 
when one pathway is altered, a cell can compensate by using less efficient 
alternative pathways.   
LPAAT3 overexpression similarly had an effect on anterograde 
trafficking from the Golgi to the plasma membrane.  I tested the secretion of a 
small protein ssHRP.  In cells overexpressing LPAAT3, ssHRP secretion was 
slower and in cells knocked down for LPAAT3, it was faster.  Cells 
overexpreesing LPAAT3 mutant had similar secretion kinetics as control cells.  
The rapid secretion observed in cells knocked down for LPAAT3 could be  
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Figure 6-2: Lipid Metabolic Pathways.  Phospholipid metabolic pathways that 
may have important roles in membrane trafficking including phosphatidic acid 
(PA), diacylglycerol (DAG) and ceremides.  Figure is modified from 
(Fernandez-Ulibarri, Vilella et al. 2007).
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slowed by the expression of a siRNA-resistant version of LPAAT3. The 
transmembrane protein VSV-G was also slower to arrive at the plasma 
membrane and accumulated in the Golgi complex for both LPAAT3 
overexpression and knockdown cells.  It is unclear why LPAAT3 knockdown 
would slow VSV-G trafficking, but measurements may have been misleading 
since the Golgi is fragmented in those cells, which made measuring Golgi 
fluorescence very difficult.  Nevertheless, LPAAT3 has an effect on Golgi 
trafficking including retrograde trafficking from the Golgi to the ER and 
anterograde trafficking from the Golgi to the cell surface.   
LPAAT3 may alter Golgi trafficking by regulating membrane tubules.  
Membrane tubules are involved in constitutive retrograde trafficking and have 
been observed forming transport carriers at the TGN.  Alternatively, LPAAT3 
may have a role in forming Golgi vesicles for the transport of cargo molecules.  
Figure 6-1 shows these two models for how LPAATs may affect membrane 
tubules.  To test these hypotheses, I assayed for Golgi membrane tubule 
formation in vitro in cells overexpressing LPAAT3.  The isolated Golgi failed to 
form tubules like the control Golgi.  In cells treated with BFA, the number and 
lengths of Golgi tubules were measured in cells overexpressing LPAAT3.  I 
found that cells overexpressing LPAAT3 formed fewer membrane tubules, 
shorter membrane tubules, and tubules that took longer to form.  Finally, in 
vitro COPI vesicle budding assays showed that while LPAAT3 Golgi formed 
slightly fewer vesicles; however, it was not statistically significant.  This has led 
us to the conclusion that LPAAT3 may be a negative regulator of membrane 
tubules, and that LPAATs may consume lysophospholipids generated by PLA2 
enzymes (Figure 6-1a). 
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Figure 6-3:  Secretory and retrograde trafficking pathways dependant on PLA2 
and LPAAT activity.  This study has demonstrated the roles of LPAAT3 and 
PLA2s in various membrane trafficking pathways including anterograde and 
retrograde pathways.  This may be due to their abilities to form/regulate 
membrane tubules.  Pathways that involve the activity of PLA2s and LPAAT3 
in this study are labeled in red.   
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PLA2 enzymes may generate lysophospholipids to form membrane tubules 
and LPAATs may reduce lysophospholipids.  While a great deal is known 
about PLA2 enzymes and retrograde trafficking, less is known about PLA2 
enzymes in TGN trafficking.  However, membrane tubules are important for 
generating TGN transport carriers.  The PLA2 antagonists ONO and BEL were 
used to look at TGN tubules formed by the protein PKD-KD (protein kinase D 
– kinase dead).  PLA2 antagonists appear to be required for these tubules to 
form in a concentration-dependent manner.  ONO also inhibited TGN 
trafficking including trafficking of the aforementioned ssHRP and VSV-G.  This 
adds to our understanding of how PLA2 enzymes are important for membrane 
tubule formation and TGN trafficking.   
Lipid turnover is the iterative synthesis and hydrolysis of phospholipids, 
neutral lipids, sphingolipids, and ceramides within the cell.  Numerous 
biosynthetic and metabolic pathways link different lipid species allowing a cell 
to rapidly alter lipid content without having to make new lipids from basic 
components.  LPAAT3 can regulate levels of LPA and PA within membranes.  
Overexpression of LPAAT3 increases PA levels and decreases LPA levels 
while LPAAT3 knockdown does the reverse.  LPA and PA may have direct 
influences on membrane curvature, cell signaling, or protein recruitment; 
however, changes in LPA and PA may have an indirect effect on cellular levels 
of DAG or other phospholipids.  These downstream products may also have 
effects on trafficking; therefore LPAAT3 expression might have unforeseen 
effects on lipid turnover.     Treatment of cells with the PLA2 inhibitor ONO may 
also affect lipid turnover.  ONO increases phospholipids and decreases 
lysophospholipids.  It is still unclear which phospholipids are altered by ONO.  
Likewise, other downstream phospholipid metabolites may also be changed by 
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cells treated with ONO.  Some of the pathways involved in lipid turnover are 
shown in Figure 6-2, which has been modified from Fernandez-Ulibarri et al 
(Fernandez-Ulibarri, Vilella et al. 2007).   
LPAAT3 is the first LPAAT to be localized to the Golgi complex and the 
first LPAAT shown to have a role in membrane trafficking.    We have a clearer 
understanding of how LPAATs and PLA2 enzymes are involved in altering 
phospholipids in organelle membranes and how those changes can affect 
critical cellular functions like membrane trafficking.  Key trafficking pathways 
that use PLA2 enzymes and LPAAT3 are shown in Figure 6-3.  Although some 
questions still remain about which phospholipid species are the predominant 
players in trafficking and what pathways are the primary metabolic routes to 
synthesizing and regulating those lipids, it is apparent that phospholipids are 
as important as their protein counterparts in secretion.
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